# EDGAR Filing Document

**Accession Number:** 0001601485
**File Stem:** 0001601485-25-000124
**Filing Date:** 2025-11
**Character Count:** 150071
**Document Hash:** 8d6dc29171795be11e3fbdd82208d965
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001601485-25-000124.hdr.sgml**: 20251113

**ACCESSION NUMBER**: 0001601485-25-000124

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 83

**CONFORMED PERIOD OF REPORT**: 20250930

**FILED AS OF DATE**: 20251113

**DATE AS OF CHANGE**: 20251113

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Elicio Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001601485
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 113430072
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39990
- **FILM NUMBER:** 251478485

**BUSINESS ADDRESS:**
- **STREET 1:** 451 D STREET, 5TH FLOOR
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02210
- **BUSINESS PHONE:** (857) 209-0050

**MAIL ADDRESS:**
- **STREET 1:** 451 D STREET, 5TH FLOOR
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02210

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Angion Biomedica Corp.
- **DATE OF NAME CHANGE:** 20140228

?xml version='1.0' encoding='ASCII'? angn-20250930

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

_____________________________________________

**FORM 10-Q**

_____________________________________________

☒ **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the quarterly period ended September 30, 2025**

**OR**

☐ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the transition period from to** 

**Commission file number 001-39990**

**Elicio Therapeutics, Inc.**

**(Exact name of registrant as specified in its charter)**

---

| | |
|:---|:---|
| **Delaware** | **11-3430072** |
| (State or other jurisdiction of<br>incorporation or organization) | (I.R.S. Employer Identification No.) |
| **451 D Street, 5th Floor Boston, Massachusetts** | **02210** |
| (Address of Principal Executive Offices) | (Zip Code) |

---

**(857) 209-0050**

Registrant's telephone number, including area code

**Securities registered pursuant to Section 12(b) of the Act:** 

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock, par value $0.01 | ELTX | The Nasdaq Capital Market |

---

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports); and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
| | | Emerging growth company | ☒ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

The number of shares of the registrant's common stock outstanding as of November 10, 2025 was 17,489,516.

------

---

| | |
|:---|:---|
| **TABLE OF CONTENTS** | |
| **<u>[PART I FINANCIAL INFORMATION](#i48b4e94dc81c43c39c91c977a31d007f_19)</u>** | **Page** |
| <u>[Item 1. Financial Statements](#i48b4e94dc81c43c39c91c977a31d007f_22)</u> | <u>[5](#i48b4e94dc81c43c39c91c977a31d007f_22)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Condensed Consolidated Balance Sheets (unaudited)](#i48b4e94dc81c43c39c91c977a31d007f_25)</u> | <u>[5](#i48b4e94dc81c43c39c91c977a31d007f_25)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)](#i48b4e94dc81c43c39c91c977a31d007f_31)</u> | <u>[6](#i48b4e94dc81c43c39c91c977a31d007f_31)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Condensed Consolidated Statements of Stockholders' Equity (Deficit) (unaudited)](#i48b4e94dc81c43c39c91c977a31d007f_34)</u> | <u>[7](#i48b4e94dc81c43c39c91c977a31d007f_34)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Condensed Consolidated Statements of Cash Flows (unaudited)](#i48b4e94dc81c43c39c91c977a31d007f_40)</u> | <u>[9](#i48b4e94dc81c43c39c91c977a31d007f_40)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Notes to Unaudited Interim Condensed Consolidated Financial Statements](#i48b4e94dc81c43c39c91c977a31d007f_43)</u> | <u>[10](#i48b4e94dc81c43c39c91c977a31d007f_43)</u> |
| <u>[Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](#i48b4e94dc81c43c39c91c977a31d007f_100)</u> | <u>[23](#i48b4e94dc81c43c39c91c977a31d007f_100)</u> |
| <u>[Item 3. Quantitative and Qualitative Disclosures](#i48b4e94dc81c43c39c91c977a31d007f_124)</u> | <u>[31](#i48b4e94dc81c43c39c91c977a31d007f_124)</u> |
| <u>[Item 4. Controls and Procedures](#i48b4e94dc81c43c39c91c977a31d007f_127)</u> | <u>[31](#i48b4e94dc81c43c39c91c977a31d007f_127)</u> |
| **<u>[PART II OTHER INFORMATION](#i48b4e94dc81c43c39c91c977a31d007f_130)</u>** |  |
| <u>[Item 1. Legal Proceedings](#i48b4e94dc81c43c39c91c977a31d007f_133)</u> | <u>[32](#i48b4e94dc81c43c39c91c977a31d007f_133)</u> |
| <u>[Item 1A. Risk Factors](#i48b4e94dc81c43c39c91c977a31d007f_136)</u> | <u>[33](#i48b4e94dc81c43c39c91c977a31d007f_136)</u> |
| <u>[Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](#i48b4e94dc81c43c39c91c977a31d007f_139)</u> | <u>[34](#i48b4e94dc81c43c39c91c977a31d007f_139)</u> |
| <u>[Item 3. Defaults Upon Senior Securities](#i48b4e94dc81c43c39c91c977a31d007f_142)</u> | <u>[34](#i48b4e94dc81c43c39c91c977a31d007f_142)</u> |
| <u>[Item 4. Mine Safety Disclosures](#i48b4e94dc81c43c39c91c977a31d007f_145)</u> | <u>[34](#i48b4e94dc81c43c39c91c977a31d007f_145)</u> |
| <u>[Item 5. Other Information](#i48b4e94dc81c43c39c91c977a31d007f_148)</u> | <u>[34](#i48b4e94dc81c43c39c91c977a31d007f_148)</u> |
| <u>[Item 6. Exhibits](#i48b4e94dc81c43c39c91c977a31d007f_151)</u> | <u>[35](#i48b4e94dc81c43c39c91c977a31d007f_151)</u> |
| <u>[Signatures](#i48b4e94dc81c43c39c91c977a31d007f_154)</u> | <u>[36](#i48b4e94dc81c43c39c91c977a31d007f_154)</u> |

---

------

<u>[**Table of Contents**](#i48b4e94dc81c43c39c91c977a31d007f_13)</u>

**Forward-Looking Statements**

This Quarterly Report on Form 10-Q, including the section titled "Management's Discussion and Analysis of Financial Condition and Results of Operations", contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this Quarterly Report on Form 10-Q other than statements of historical fact, including statements concerning our business strategy and plans, future operating results and financial position, as well as our objectives and expectations for our future operations, are forward-looking statements.

In some cases, you can identify forward-looking statements by terminology such as "aim," "anticipate," "assume," "believe," "contemplate," "continue," "could," "due," "estimate," "expect," "goal," "intend," "may," "objective," "plan," "predict," "potential," "positioned," "seek," "should," "target," "will," "would," and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. These forward-looking statements include, but are not limited to, statements about:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our financial condition, including our ability to obtain the funding necessary to advance the development of ELI-002 7P and any other current or future product candidates, our ability to continue as a going concern and our cash runway;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the ability of our clinical trials to demonstrate safety and efficacy of our product candidates, and other positive results;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to utilize our platform to develop a pipeline of product candidates to address unmet needs in cancer;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the timing, progress and results of clinical trials for ELI-002 7P, and other current or future product candidates we may develop, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the studies or trials will become available, and the timing, progress and results of our research and development programs;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the timing, scope and likelihood of regulatory filings and approvals, including timing of Investigational New Drug applications and U.S. Food and Drug Administration ("FDA") approval of ELI-002 7P and any current or future product candidates;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the timing, scope or likelihood of foreign regulatory filings and approvals;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to develop and advance our current product candidates and programs into, and successfully complete, clinical studies;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our manufacturing, commercialization, and marketing capabilities and strategy;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the need to hire additional personnel and our ability to attract and retain such personnel;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the size of the market opportunity for our product candidates, including estimates of the number of patients who suffer from the diseases we are targeting;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• expectations regarding the approval and use of our product candidates in combination with other drugs;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• expectations regarding potential for accelerated approval or other expedited regulatory designation;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our competitive position and the success of competing therapies that are or may become available;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our anticipated research and development activities and projected expenditures;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• existing regulations and regulatory developments in the United States, Europe and other jurisdictions;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the extent to which global economic and political developments, including the ongoing conflict between Ukraine and Russia, the conflicts in the Middle East, including the conflict between Israel and Palestine, geopolitical tensions with China, and other geopolitical events, as well as the macroeconomic conditions, including tariffs, inflation, volatility in interest rates, potential for economic slowdown or recession and potential governmental shutdowns, will affect our business operations, clinical trials, or financial condition;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our expectations regarding other macroeconomic trends;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our intellectual property position, including the scope of protection we are able to establish and maintain for intellectual property rights covering ELI-002 7P, other current or future product candidates we may develop, including the extensions of existing patent terms where available, the validity of intellectual property rights held by third parties, and our ability not to infringe, misappropriate or otherwise violate any third-party intellectual property rights;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our continued reliance on third parties to conduct additional clinical trials of our product candidates, and for the manufacture of our product candidates for clinical trials;

------

<u>[**Table of Contents**](#i48b4e94dc81c43c39c91c977a31d007f_13)</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to have manufactured sufficient supplies of drug product for clinical testing and commercialization;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to obtain, and negotiate favorable terms of, any collaboration, licensing or other arrangements that may be necessary or desirable to develop, manufacture or commercialize our product candidates;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our projected financial performance;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our anticipated use of proceeds from potential financing activities;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the period over which we estimate our existing cash and cash equivalents will be sufficient to fund our planned operating expenses and capital expenditure requirements;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the potential impact of anticipated funding pressures and the expected effect from U.S. export controls and tariffs; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the impact of laws and regulations.

We caution you that the foregoing list may not contain all of the forward-looking statements made in this Quarterly Report on Form 10-Q.

Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. We discuss these risks in greater detail under the sections titled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2024 (the "Form 10-K") filed with the U.S. Securities and Exchange Commission ("SEC") on March 31, 2025, our Quarterly Report on Form 10-Q for the quarter ended March 31, 2025 filed with the SEC on May 13, 2025, and our Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 filed with the SEC on August 7, 2025, as updated and/or supplemented in subsequent filings with the SEC. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Also, forward-looking statements represent our management's beliefs and are based on assumptions as of the date they were made. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. While we believe that information provides a reasonable basis for these statements, that information may be limited or incomplete. Our statements should not be read to indicate that we have conducted an exhaustive inquiry into or review of all relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely on these statements.

This Quarterly Report on Form 10-Q also contains estimates, projections and other information concerning our industry, our business and the markets for certain drugs, including data regarding the estimated size of those markets, their projected growth rates and the incidence of certain medical conditions. Information that is based on estimates, forecasts, projections or similar methodologies is inherently subject to uncertainties, and actual events or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise expressly stated, we obtained this industry, business, market and other data from reports, research surveys, studies and similar data prepared by third parties, industry, medical and general publications, government data and similar sources. In some cases, we do not expressly refer to the sources from which this data is derived. In that regard, when we refer to one or more sources of this type of data in any paragraph, you should assume that other data of this type appearing in the same paragraph is derived from the same sources, unless otherwise expressly stated or the context otherwise requires.

In this Quarterly Report on Form 10-Q, unless the context indicates otherwise, the terms "Company," "Elicio," "we," "us," and "our" refer to Elicio Therapeutics, Inc. and our wholly-owned subsidiaries.

**Trademarks**

This Quarterly Report on Form 10-Q includes trademarks, service marks and trade names owned by us or other companies. All trademarks, service marks and trade names included in this Quarterly Report on Form 10-Q are the property of their respective owners. We do not intend our use or display of other companies' trade names or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other companies.

------

<u>[**Table of Contents**](#i48b4e94dc81c43c39c91c977a31d007f_13)</u>

**Part I FINANCIAL INFORMATION**

**Item 1. Financial Statements**

**ELICIO THERAPEUTICS, INC.** 

**Condensed Consolidated Balance Sheets** 

**(in thousands, except share and per share amounts)**

**(unaudited)**

---

| | | |
|:---|:---|:---|
| | **September 30,<br>2025** | **December 31,<br>2024** |
| **Assets** | | |
| Current assets |  |  |
| &nbsp;&nbsp;&nbsp;Cash and cash equivalents | $20611 | $17618 |
| &nbsp;&nbsp;&nbsp;Restricted cash, current |  | 1178 |
| &nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | 854 | 1897 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current assets | 21465 | 20693 |
| &nbsp;&nbsp;&nbsp;Property and equipment, net | 328 | 483 |
| &nbsp;&nbsp;&nbsp;Operating lease, right-of-use assets | 5019 | 5706 |
| &nbsp;&nbsp;&nbsp;Restricted cash, noncurrent | 702 | 696 |
| &nbsp;&nbsp;&nbsp;Other long-term prepaid assets | 770 | 600 |
| **Total assets** | $**28284** | $**28178** |
| **Liabilities and stockholders' equity (deficit)** |  |  |
| Current liabilities |  |  |
| &nbsp;&nbsp;&nbsp;Accounts payable | $321 | $1038 |
| &nbsp;&nbsp;&nbsp;Accrued expenses | 5213 | 8415 |
| &nbsp;&nbsp;&nbsp;Deferred research obligation |  | 1169 |
| &nbsp;&nbsp;&nbsp;Operating lease liability, current | 981 | 901 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities | 6515 | 11523 |
| &nbsp;&nbsp;&nbsp;Warrant liabilities | 3877 | 2828 |
| &nbsp;&nbsp;&nbsp;Operating lease liability, noncurrent | 4356 | 5105 |
| &nbsp;&nbsp;&nbsp;Long-term debt, net of debt discount and debt issuance costs | 9720 | 20034 |
| **Total liabilities** | 24468 | 39490 |
| Commitments and contingencies - Note 9 |  |  |
| Stockholders' equity (deficit): |  |  |
| Common stock, $0.01 par value per share; 300,000,000 shares authorized; 17,273,107 shares and 11,043,837 shares issued at September 30, 2025 and December 31, 2024, respectively; 17,258,652 and 11,029,382 outstanding as of September 30, 2025 and December 31, 2024, respectively | 173 | 110 |
| Treasury stock, at cost, 14,455 shares outstanding | (150) | (150) |
| Additional paid-in capital | 229778 | 183004 |
| Accumulated other comprehensive loss | (31) | (175) |
| Accumulated deficit | (225954) | (194101) |
| Total stockholders' equity (deficit) | 3816 | (11312) |
| **Total liabilities and stockholders' equity (deficit)** | $**28284** | $**28178** |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

*The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.*

------

<u>[**Table of Contents**](#i48b4e94dc81c43c39c91c977a31d007f_13)</u>

**ELICIO THERAPEUTICS, INC.** 

**Condensed Consolidated Statements of Operations and Comprehensive Loss**

**(in thousands, except share and per share amounts)**

**(unaudited)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended <br>September 30,** | **Three Months Ended <br>September 30,** | **Nine Months Ended <br>September 30,** | **Nine Months Ended <br>September 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| **Operating expenses:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Research and development | $5039 | $7208 | $19823 | $22947 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;General and administrative | 3006 | 3136 | 9049 | 8563 |
| Total operating expenses | 8045 | 10344 | 28872 | 31510 |
| **Loss from operations** | **(8045)** | **(10344)** | **(28872)** | **(31510)** |
| Other (expense) income |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Change in fair value of warrant liabilities | (1811) | (5617) | (3177) | (3279) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Loss on issuance of pre-funded warrants |  | (2924) |  | (3502) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gain on sale of equipment |  |  |  | 3 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Foreign exchange transaction (loss) gain |  | (1) |  | 143 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Grant income |  |  | 415 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest income | 199 | 185 | 577 | 472 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest expense | (426) | (137) | (796) | (221) |
| Total other (expense), net | (2038) | (8494) | (2981) | (6384) |
| **Net loss** | **(10083)** | **(18838)** | **(31853)** | **(37894)** |
| **Other comprehensive income (loss):** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Foreign currency translation adjustment | 39 | 36 | 144 | (5) |
| **Comprehensive loss** | $**(10044)** | $**(18802)** | $**(31709)** | $**(37899)** |
| Net loss per common share, basic and diluted | $(0.60) | $(1.39) | $(2.09) | $(3.23) |
| Weighted average common shares and pre-funded warrants outstanding, basic and diluted | 16692476 | 13582345 | 15247864 | 11720527 |

---

*The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.*

------

<u>[**Table of Contents**](#i48b4e94dc81c43c39c91c977a31d007f_13)</u>

**ELICIO THERAPEUTICS, INC.** 

**Condensed Consolidated Statements of Stockholders' Equity (Deficit)**

**(in thousands, except share amounts)**

**(unaudited)**

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Common Stock** | **Common Stock** | **Treasury Stock** | **Treasury Stock** | **Additional**<br>**Paid-in**<br>**Capital** | **Accumulated Other <br>Comprehensive Loss** | **Accumulated** <br>**Deficit** | **Total** <br>**Stockholders'**<br>**Equity (Deficit)** |
| | **Shares** | **Amount** | **Shares** | **Amount** | **Additional**<br>**Paid-in**<br>**Capital** | **Accumulated Other <br>Comprehensive Loss** | **Accumulated** <br>**Deficit** | **Total** <br>**Stockholders'**<br>**Equity (Deficit)** |
| **Balance as of December 31, 2024** | 11043837 | $110 | (14455) | $(150) | $183004 | $(175) | $(194101) | $(11312) |
| Issuance of common stock from at-the-market offering | 106823 | 1 |  |  | 834 |  |  | 835 |
| Issuance of common stock upon exercise of options | 1628 |  |  |  | 7 |  |  | 7 |
| Conversion of senior note payable into common stock, net of issuance costs of $0.3 million | 3500573 | 35 |  |  | 20141 |  |  | 20176 |
| Issuance of common stock and warrants from the January 2025 Offering, net of issuance costs of $0.8 million | 1261830 | 13 |  |  | 9130 |  |  | 9143 |
| Issuance of common stock upon the exercise of common warrants | 68500 | 1 |  |  | 715 |  |  | 716 |
| Stock-based compensation |  |  |  |  | 517 |  |  | 517 |
| Foreign currency translation adjustment |  |  |  |  |  | 31 |  | 31 |
| Net loss |  |  |  |  |  |  | (11209) | (11209) |
| **Balance as of March 31, 2025** | 15983191 | 160 | (14455) | (150) | 214348 | (144) | (205310) | 8904 |
| Issuance of common stock upon exercise of stock options | 12499 |  |  |  | 50 |  |  | 50 |
| Issuance of common warrants associated with June 2025 Promissory Note |  |  |  |  | 641 |  |  | 641 |
| Issuance of common stock from at-the-market offering, net of issuance costs of $0.1 million | 281697 | 3 |  |  | 2013 |  |  | 2016 |
| Stock-based compensation |  |  |  |  | 710 |  |  | 710 |
| Foreign currency translation adjustment |  |  |  |  |  | 74 |  | 74 |
| Net loss |  |  |  |  |  |  | (10561) | (10561) |
| **Balance as of June 30, 2025** | 16277387 | 163 | (14455) | (150) | 217762 | (70) | (215871) | 1834 |
| Issuance of common stock upon exercise of stock options | 17791 |  |  |  | 88 |  |  | 88 |
| Issuance of common stock upon the exercise of common warrants | 190000 | 2 |  |  | 2703 |  |  | 2705 |
| Issuance of common stock from at-the-market offering, net of issuance costs of $0.3 million | 787929 | 8 |  |  | 8527 |  |  | 8535 |
| Stock-based compensation |  |  |  |  | 698 |  |  | 698 |
| Foreign currency translation adjustment |  |  |  |  |  | 39 |  | 39 |
| Net loss |  |  |  |  |  |  | (10083) | (10083) |
| **Balance as of September 30, 2025** | 17273107 | $173 | (14455) | $(150) | $229778 | $(31) | $(225954) | $3816 |

---

------

<u>[**Table of Contents**](#i48b4e94dc81c43c39c91c977a31d007f_13)</u>

**ELICIO THERAPEUTICS, INC.** 

**Condensed Consolidated Statements of Stockholders' Equity (Deficit) (continued)**

**(in thousands, except share amounts)**

**(unaudited)**

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Common Stock** | **Common Stock** | **Treasury Stock** | **Treasury Stock** | **Additional**<br>**Paid-in**<br>**Capital** | **Accumulated Other <br>Comprehensive Loss** | **Accumulated** <br>**Deficit** | **Total** <br>**Stockholders'**<br>**Equity (Deficit)** |
| | **Shares** | **Amount** | **Shares** | **Amount** | **Additional**<br>**Paid-in**<br>**Capital** | **Accumulated Other <br>Comprehensive Loss** | **Accumulated** <br>**Deficit** | **Total** <br>**Stockholders'**<br>**Equity (Deficit)** |
| **Balance as of December 31, 2023** | 9603723 | $96 | (14455) | $(150) | $153827 | $(197) | $(142203) | $11373 |
| Issuance of common stock from at-the-market offering, net of issuance costs of $0.1 million | 615363 | 6 |  |  | 5056 |  |  | 5062 |
| Issuance of common stock upon settlement of restricted stock | 903 |  |  |  | 11 |  |  | 11 |
| Stock-based compensation |  |  |  |  | 324 |  |  | 324 |
| Foreign currency translation adjustment |  |  |  |  |  | (73) |  | (73) |
| Net loss |  |  |  |  |  |  | (11827) | (11827) |
| **Balance as of March 31, 2024** | 10219989 | 102 | (14455) | (150) | 159218 | (270) | (154030) | 4870 |
| Exercise of stock options | 3391 |  |  |  | 13 |  |  | 13 |
| Issuance of common stock upon settlement of restricted stock units | 677 |  |  |  | 9 |  |  | 9 |
| Issuance of common stock from at-the-market offering | 34816 | 1 |  |  | 302 |  |  | 303 |
| Stock-based compensation |  |  |  |  | 350 |  |  | 350 |
| Foreign currency translation adjustment |  |  |  |  |  | 32 |  | 32 |
| Net loss |  |  |  |  |  |  | (7229) | (7229) |
| **Balance as of June 30, 2024** | 10258873 | 103 | (14455) | (150) | 159892 | (238) | (161259) | (1652) |
| Exercise of stock options | 5353 |  |  |  | 21 |  |  | 21 |
| Issuance of common stock upon net settlement of restricted stock units | 348 |  |  |  | 5 |  |  | 5 |
| Issuance of common stock from at-the-market offering | 9803 |  |  |  | 48 |  |  | 48 |
| Issuance of common stock from the Public Offering, net of issuance costs of $0.5 million | 510000 | 5 |  |  | 1075 |  |  | 1080 |
| Stock-based compensation |  |  |  |  | 314 |  |  | 314 |
| Foreign currency translation adjustment |  |  |  |  |  | 36 |  | 36 |
| Net loss |  |  |  |  |  |  | (18838) | (18838) |
| **Balance as of September 30, 2024** | 10784377 | $108 | (14455) | $(150) | $161355 | $(202) | $(180097) | $(18986) |

---

*The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.*

------

<u>[**Table of Contents**](#i48b4e94dc81c43c39c91c977a31d007f_13)</u>

**ELICIO THERAPEUTICS, INC.** 

**Condensed Consolidated Statements of Cash Flows**

**(in thousands)**

**(unaudited)**

---

| | | |
|:---|:---|:---|
| | **Nine Months Ended <br>September 30,** | **Nine Months Ended <br>September 30,** |
| | **2025** | **2024** |
| **Cash flows from operating activities** |  |  |
| Net loss | $(31853) | $(37894) |
| Adjustments to reconcile net loss to net cash used in operating activities: |  |  |
| &nbsp;&nbsp;&nbsp;Depreciation | 155 | 236 |
| &nbsp;&nbsp;&nbsp;Amortization of right-of-use assets, operating leases | 687 | 637 |
| &nbsp;&nbsp;&nbsp;Non-cash interest expense | 603 | 82 |
| &nbsp;&nbsp;&nbsp;Amortization of debt discount | 35 | 26 |
| &nbsp;&nbsp;&nbsp;Costs expensed upon the issuance of warrants |  | 549 |
| &nbsp;&nbsp;&nbsp;Change in fair value of warrant liabilities | 3177 | 3279 |
| &nbsp;&nbsp;&nbsp;Stock-based compensation | 1925 | 988 |
| &nbsp;&nbsp;&nbsp;Loss on issuance of warrants |  | 3502 |
| &nbsp;&nbsp;&nbsp;Gain on disposal of property and equipment, net |  | (3) |
| &nbsp;&nbsp;&nbsp;Changes in operating assets and liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | 1043 | (580) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other long-term prepaid assets | (170) | 2233 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | (717) | (2385) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued expenses | (3202) | 1095 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred research obligation | (1169) | 613 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating lease liabilities | (669) | (702) |
| Net cash used in operating activities | (30155) | (28324) |
| **Cash flows from investing activities** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Purchases of property and equipment |  | (42) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Proceeds from sale of property and equipment |  | 3 |
| Net cash used in investing activities |  | (39) |
| **Cash flows from financing activities** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Proceeds from issuance of related party convertible note |  | 19727 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Proceeds from issuance of common stock and common warrants from the January 2025 Offering | 9143 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Proceeds from issuance of common stock and common warrants |  | 22882 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Proceeds from the exercise of common warrants | 1293 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Proceeds from issuance of common stock from at-the-market offerings, net of issuance costs | 11385 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Proceeds from the June 2025 Promissory Note, net of issuance costs | 9866 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Payment of warrant issuance costs |  | (549) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Proceeds from the exercise of stock options | 145 | 34 |
| Net cash provided by financing activities | 31832 | 42094 |
| Effect of foreign currency on cash and cash equivalents | 144 | (5) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net increase in cash and cash equivalents | 1821 | 13726 |
| Cash, cash equivalents and restricted cash at the beginning of the period | 19492 | 14301 |
| **Cash, cash equivalents, and restricted cash at the end of the period** | $**21313** | $**28027** |
| **Components of cash and cash equivalents, and restricted cash** |  |  |
| Cash and cash equivalents | $20611 | $26016 |
| Restricted cash | 702 | 2011 |
| **Total cash, cash equivalents and restricted cash** | $21313 | $28027 |
| **Supplemental disclosure of noncash investing and financing activities:** |  |  |
| Fair value of pre-funded warrants at issuance date | $— | $13382 |
| Fair value of common stock warrants upon settlement | $2128 | $— |
| Fair value of common warrants issued with January 2025 Offering | $9719 | $— |
| Fair value of common warrants issued with June 2025 Promissory Note | $641 | $— |
| Fair value of common warrants at issuance date | $— | $6509 |
| Conversion of related-party senior note payable and interest into equity | $20176 | $— |
| Accretion of convertible notes discount from issuance costs | $— | $26 |
| Vesting of restricted common stock | $— | $25 |

---

*The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.*

------

<u>[**Table of Contents**](#i48b4e94dc81c43c39c91c977a31d007f_13)</u>

**ELICIO THERAPEUTICS, INC.**

**Notes to Unaudited Interim Condensed Consolidated Financial Statements**

**Note 1—Description of the Business and Financial Condition**

Elicio Therapeutics, Inc. ("Elicio" or the "Company") is a clinical-stage biotechnology company pioneering the development of immunotherapies for patients with limited treatment options and poor outcomes suffering from cancer. Elicio and its wholly-owned subsidiaries, Elicio Securities Corporation ("ESC"), an investment company, Elicio Operating Company, Inc. ("Former Elicio"), and Elicio Australia Pty Ltd. ("Elicio Pty"), an Australian subsidiary established for the purposes of qualifying for research credits for studies conducted in Australia, are collectively referred to as "Elicio" throughout these condensed consolidated financial statements.

***Liquidity and Going Concern***

The Company has experienced net losses and negative cash flows from operating activities since inception. As of September 30, 2025, the Company had an accumulated deficit of $226.0 million. The Company expects that its operating losses and negative operating cash flows will continue for the foreseeable future as the Company continues to develop its product candidates.

As of September 30, 2025, the Company had $20.6 million in cash and cash equivalents. The Company's losses from operations, negative operating cash flows and accumulated deficit, as well as the additional capital needed to fund operations for at least twelve months following the issuance of the condensed consolidated financial statements, raise substantial doubt about the Company's ability to continue as a going concern. The Company expects to incur substantial expenditures in the foreseeable future for the development of its product candidates and will require additional financing to continue this development. The Company plans to address this condition through the sale of Company common stock or other securities in public offerings and/or private placements, debt financings, or through other capital sources, including licensing arrangements, partnerships and collaborations with other companies or other strategic transactions, but there is no assurance these plans will be completed successfully or at all. If the Company is unable to obtain additional capital when and as needed to continue as a going concern, it might have to further reduce or scale back its operations and/or liquidate its assets, and the values it receives for its assets in liquidation or dissolution could be significantly lower than the values reflected in its financial statements.

The accompanying condensed consolidated financial statements have been prepared on a basis that assumes that the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

**Note 2—Summary of Significant Accounting Policies**

***Grant Income***

Grant funding for research and development received under grant agreements, where there is no obligation to repay and where the funding received is in excess of the costs incurred is recognized as grant income in the period during which the related qualifying expenses are incurred, based on the applicable reimbursement percentage, provided that the grants are fully approved by the granting agencies and the conditions under which the grants were provided have been met. The Company concluded that payments received under these grants represent conditional, nonreciprocal contributions, as described in ASC 958, *Not-for-Profit Entities*, and that the grants are not within the scope of ASC 606, *Revenue from Contracts with Customers*, as the organizations providing the grants do not meet the definition of a customer. Expenses for grants are tracked by using a project code specific to the grant. Employees also track hours worked by using the project code.

Please refer to Note 2 – "Summary of Significant Accounting Policies" to the Company's consolidated financial statements from the Form 10-K for the discussion of the Company's significant accounting policies.

***Basis of Presentation***

The accompanying condensed consolidated interim financial statements have been prepared in accordance with U.S. generally accepted accounting principles ("U.S. GAAP"). Any references in these notes to applicable guidance are meant to refer to U.S. GAAP as found in Accounting Standards Codification ("ASC") and Accounting Standards Update ("ASU") promulgated by the Financial Accounting Standards Board ("FASB").

------

<u>[**Table of Contents**](#i48b4e94dc81c43c39c91c977a31d007f_13)</u>

**ELICIO THERAPEUTICS, INC.** 

**Notes to Unaudited Interim Condensed Consolidated Financial Statements (Continued)**

The consolidated interim financial statements include the accounts of the Company and its wholly-owned subsidiaries, Elicio Pty, ESC, and Former Elicio. All significant intercompany balances and transactions have been eliminated. These interim financial statements are unaudited and reflect all normal recurring adjustments that are, in the opinion of management, necessary for the fair statement of such interim financial statements. The December 31, 2024 condensed consolidated balance sheet data was derived from audited financial statements but does not include all disclosures required by U.S. GAAP for complete financial statements. The accompanying financial information should be read in conjunction with the consolidated financial statements and notes thereto contained in the Form 10-K.

***Recently Issued Accounting Standards Not Yet Adopted***

From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. Except as noted below, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its condensed consolidated financial statements and disclosures.

In December 2023, the FASB issued ASU No. 2023-09, *Income Taxes (Topic 740): Improvements to Income Tax Disclosures* ("ASU 2023-09")*.* This ASU requires disaggregated information about a reporting entity's effective tax rate reconciliation as well as additional information on income taxes paid. The standard requires entities to disclose federal, state, and foreign income taxes in their rate reconciliation tables and elaborate on reconciling items that exceed a quantitative threshold. Additionally, it requires an annual disclosure of income taxes paid, net of refunds, categorized by jurisdiction based on a quantitative threshold. The ASU is effective on a prospective basis for annual periods beginning after December 15, 2024. Early adoption is permitted. This ASU will result in the required additional disclosures being included in the Company's consolidated financial statements, once adopted. The Company is currently evaluating the effect that adoption of ASU 2023-09 will have on its consolidated financial statements.

In November 2024, the FASB issued ASU No. 2024-03, *Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures* ("ASU 2024-03"). This ASU requires enhanced disclosures of disaggregated income statement expenses. Disclosure within the notes to the financial statements for each annual and interim period should include: employee compensation, depreciation, and intangible asset amortization, included in each relevant expense caption; certain amounts that are already required to be disclosed under current U.S. GAAP in the same disclosure as the other disaggregation requirement; a qualitative description of the amounts remaining in relevant expense captions that are not separately disaggregated quantitatively; and the total amount of selling expenses and, in annual reporting periods, an entity's definition of selling expenses. For public entities, the provisions within ASU 2024-03 (as further clarified through ASU No. 2025-01, *Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures* (Subtopic 220-40)) are effective for the first annual reporting period beginning after December 15, 2026 and for interim reporting periods after December 15, 2027. The provisions within ASU 2024-03 are required to be applied prospectively; however, such provisions may be applied retrospectively for all comparative periods following the effective date. The Company is currently evaluating the effect that adoption of ASU 2024-03 will have on its consolidated financial statements.

In November 2024, the FASB issued ASU No. 2024-04, *Debt – Debt with Conversion and Other Options (Subtopic 470-20): Induced Conversions of Convertible Debt Instruments* ("ASU 2024-04"). This new guidance clarifies the accounting treatment of whether the settlement of convertible debt should be accounted for as an induced conversion or extinguishment of convertible debt. This guidance is effective for annual reporting periods beginning after December 15, 2025. The Company is currently evaluating the effect that adoption of ASU 2024-04 will have on its consolidated financial statements.

**Note 3—Fair Value Measurements**

The following tables present the Company's financial assets and liabilities measured at fair value on a recurring basis and their assigned levels within the fair value hierarchy (in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **September 30, 2025** | **September 30, 2025** | **September 30, 2025** | **September 30, 2025** |
| | **Level 1** | **Level 2** | **Level 3** | **Total** |
| Money market funds<sup>(1)</sup> | $6189 | $— | $— | $6189 |
| **Total assets** | $6189 | $— | $— | $6189 |
| Warrant liabilities | $— | $3872 | $5 | $3877 |
| **Total liabilities** | $— | $3872 | $5 | $3877 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **December 31, 2024** | **December 31, 2024** | **December 31, 2024** | **December 31, 2024** |
| | **Level 1** | **Level 2** | **Level 3** | **Total** |
| Money market funds<sup>(1)</sup> | $12100 | $— | $— | $12100 |
| **Total assets** | $12100 | $— | $— | $12100 |
| Warrant liabilities | $— | $2827 | $1 | $2828 |
| **Total liabilities** | $— | $2827 | $1 | $2828 |

---

_________________

(1) Included in cash, cash equivalents, and restricted cash on the condensed consolidated balance sheets. This balance includes cash requirements settled on a nightly basis.

Cash equivalents at September 30, 2025 and December 31, 2024 were held in U.S. Treasury securities.

There were no transfers made among the three levels in the fair value hierarchy during the periods presented.

The fair value of the warrants assumed in the merger (the "Merger") with Angion Biomedica Corp. ("Angion" and the warrants, the "Angion Warrants") were classified as Level 3 with key Level 3 inputs of exercise price, term, and volatility. The following table presents a summary of changes in Level 3 in the fair value of the Company's common stock warrant liability (in thousands):

---

| | | |
|:---|:---|:---|
| | **For the nine months ended,**<br>**September 30,<br>2025** | **For the year ended,**<br>**December 31,<br>2024** |
| Balance, beginning of the period | $1 | $11 |
| Change in fair value | 4 | (10) |
| Balance, end of the period | $5 | $1 |

---

Both observable and unobservable inputs were used to determine the fair value of positions that the Company has classified within the Level 3 category. Unrealized gains and losses associated with assets and liabilities within the Level 3 category include changes in fair value that were attributable to both observable (e.g., changes in market interest rates) and unobservable (e.g., changes in unobservable long-dated volatilities) inputs.

The fair value of the Angion Warrants issued by the Company has been estimated using the Black-Scholes option pricing model. The underlying equity included in Black-Scholes was valued based on the equity value implied from sales of preferred and common stock at each measurement date, as applicable. The fair value of the Angion Warrants was impacted by the model selected as well as assumptions surrounding unobservable inputs including the underlying equity value, expected volatility of the underlying equity, risk-free interest rate, and the expected term.

The fair value of the assumed Angion Warrant liability was estimated using the following assumptions:

---

| | | |
|:---|:---|:---|
| | **September 30,<br>2025** | **December 31,<br>2024** |
| Weighted average strike price | $76.00 | $76.00 |
| Contractual term (years) | 2.9 | 3.7 |
| Volatility (annual) | 80.3% | 74.9% |
| Risk-free rate | 3.8% | 4.4% |
| Dividend yield (per share) | —% | —% |

---

In July 2024, the Company closed an underwritten public offering (the "Public Offering"), consisting of (i) 500,000 shares of the Company's common stock (the "July 2024 Shares"), (ii) pre-funded warrants exercisable for 1,800,000 shares of common stock (the "July 2024 Pre-Funded Warrants"), and (iii) common warrants to purchase up to 2,300,000 shares of common stock (the "July 2024 Common Warrants"). Each July 2024 Pre-Funded Warrant issued and sold in the Public Offering is exercisable at an exercise price equal to $0.01 per share, subject to certain adjustments and limitations as provided under the terms of the July 2024 Pre-Funded Warrants. As of the current reporting period end, the outstanding July 2024 Pre-Funded Warrants are equity classified. The Company identified the July 2024 Common Warrants as liabilities and measured them at fair value on July 1, 2024, and subsequently remeasures the fair value of these warrant liabilities at each reporting period end. The Company is able to calculate the fair value measurement based on directly observable inputs from active markets, therefore these warrants are classified as Level 2. Refer to Note 6 and 8 for further discussion. Each July 2024 Common Warrant is exercisable at an exercise price equal to $5.00 per share, subject to certain adjustments and limitations as provided under the terms of the July 2024 Common Warrants. At the Company's annual stockholder's meeting in November 2024, the Company obtained stockholder approval for GKCC, LLC ("GKCC"), together with its affiliates, to exceed the 19.99% beneficial ownership limitation pursuant to the rules and regulations of the Nasdaq Stock Market LLC ("Nasdaq") ("Stockholder Approval"). As a result of obtaining Stockholder Approval, certain July 2024 Common Warrants are equity classified while the remainder of the outstanding July 2024 Common Warrants are liability classified and are subsequently remeasured at each reporting period end.

For the three and nine months ended September 30, 2025, the Company recognized a change in fair value of $1.8 million and $3.2 million, respectively.

The Company records the fair value remeasurement of the outstanding liability-classified warrants in change in fair value of warrant liabilities in the condensed consolidated statements of operations and comprehensive loss included in this Quarterly Report on Form 10-Q.

**Note 4—Balance Sheet Components**

***Prepaid and Other Current Assets***

Prepaid and other current assets consisted of the following (in thousands):

---

| | | |
|:---|:---|:---|
| | **September 30,<br>2025** | **December 31,<br>2024** |
| Prepaid research and development contract services | $107 | $1206 |
| Advanced professional fees | 238 | 243 |
| Prepaid insurance | 444 | 347 |
| Other prepaid expenses and other current assets | 65 | 101 |
| &nbsp;&nbsp;Total prepaid and other current assets | $854 | $1897 |

---

------

<u>[**Table of Contents**](#i48b4e94dc81c43c39c91c977a31d007f_13)</u>

**ELICIO THERAPEUTICS, INC.** 

**Notes to Unaudited Interim Condensed Consolidated Financial Statements (Continued)**

***Property and Equipment, Net***

Property and equipment, net was comprised of the following (in thousands):

---

| | | |
|:---|:---|:---|
| | **September 30,<br>2025** | **December 31,<br>2024** |
| Equipment | $1661 | $1661 |
| Furniture and fixtures | 242 | 242 |
| Leasehold improvements | 132 | 132 |
| &nbsp;&nbsp;Total property and equipment | 2035 | 2035 |
| Less: accumulated depreciation | (1707) | (1552) |
| &nbsp;&nbsp;Property and equipment, net | $328 | $483 |

---

Depreciation expense for the three and nine months ended September 30, 2025 was $0.1 million and $0.2 million, respectively. For the three and nine months ended September 30, 2024, depreciation expense was immaterial and $0.2 million, respectively.

***Other long-term prepaid assets***

Other long-term prepaid assets consisted of the advance payments for clinical trial services, totaling $0.8 million and $0.6 million for September 30, 2025 and December 31, 2024, respectively.

***Accrued Expenses***

Accrued expenses consisted of the following (in thousands):

---

| | | |
|:---|:---|:---|
| | **September 30,<br>2025** | **December 31,<br>2024** |
| Accrued professional fees | $761 | $1167 |
| Accrued compensation and benefits | 1688 | 2312 |
| Accrued research and development | 2714 | 4910 |
| Other accrued expenses | 50 | 26 |
| &nbsp;&nbsp;Total accrued expenses | $5213 | $8415 |

---

**Note 5 — Research Grants**

In September 2022, Former Elicio entered into a grant agreement with the Gastro-Intestinal ("GI") Research Foundation, a not-for-profit organization focused on supporting research to treat, cure, and prevent digestive diseases. Of the $2.8 million award, $2.3 million was received in September 2022 and the remaining $0.5 million was received in June 2023 with the completion of the development efforts as defined in the grant agreement. The final $0.5 million payment was applied as a credit to the second grant agreement described below.

In September 2023, the Company entered into a second grant agreement with the GI Research Foundation for $3.1 million, with such amount received net of the $0.5 million credit described above. For the three and nine months ended September 30, 2024, the Company incurred $0 and $2.2 million in research and development expenses related to this project, respectively. As of September 30, 2024, the grant funds available for the second grant agreement were $0 and the deferred research obligation was $0, as the second grant agreement activities were completed in the third quarter of 2024.

In August 2024, the Company entered into a third grant agreement with the GI Research Foundation for $1.5 million. For each of the three and nine months ended September 30, 2024, the Company incurred $0.2 million in research and development expenses related to this project, all of which was reimbursed from available grant funds. For the three and nine months ended September 30, 2025, the Company incurred $0 and $0.8 million in research and development expenses related to this project, respectively, of which $0 and $0.8 million was reimbursed from available grant funds, respectively. The third grant agreement activities were completed in the second quarter of 2025.

------

<u>[**Table of Contents**](#i48b4e94dc81c43c39c91c977a31d007f_13)</u>

**ELICIO THERAPEUTICS, INC.** 

**Notes to Unaudited Interim Condensed Consolidated Financial Statements (Continued)**

The award money for the three grant agreements was recorded as contra-expense to offset the research and development costs incurred. Following completion of the third grant agreement with GI Research Foundation, during 2025, the remaining $0.4 million of the grant funds were recognized as grant income, as there were no further conditions to be met.

**Note 6—Common Stock and Stockholders' Equity**

***Authorized Shares***

The Company's current Amended and Restated Certificate of Incorporation, as amended, authorizes 300,000,000 shares of common stock, par value $0.01 per share, and 10,000,000 shares of preferred stock, par value $0.01 per share.

***At-The-Market Equity Programs***

In May 2022, the Company filed a registration statement on Form S-3 (the "Prior Shelf Registration Statement") with the SEC that registered the offering, issuance, and sale of an amount of common stock, preferred stock, debt securities, and warrants to purchase common stock, preferred stock and/or debt securities, not to exceed an aggregate initial offering price of $100 million. Simultaneously, the Company entered into an At-the-Market Equity Offering Sales Agreement with Stifel, Nicolaus & Company, Incorporated and Virtu Americas LLC, as sales agents, that provided for the issuance and sale of up to $21 million of shares of common stock from time to time in "at-the-market" offerings under the Prior Shelf Registration Statement and related prospectus filed with the Prior Shelf Registration Statement (the "2022 ATM Program"). During the nine months ended September 30, 2024, the Company issued and sold a total of 650,179 shares of common stock at a weighted average price of $8.42 per share under the 2022 ATM Program for aggregate net sale proceeds of approximately $5.4 million after deducting sales commissions. In May 2024, the 2022 ATM Program was terminated by the Company.

In June 2024, the Company filed a registration statement on Form S-3 (the "2024 Registration Statement") with the SEC that registered the offering, issuance, and sale of an amount of common stock, preferred stock, debt securities, warrants to purchase common stock, preferred stock and/or debt securities, and/or units consisting of any combination of such securities, not to exceed an aggregate initial offering price of $200 million. Simultaneously, the Company entered into the Capital on Demand<sup>TM</sup> Sales Agreement with JonesTrading Institutional Services LLC, as agent, to provide for the issuance and sale of up to $40 million of shares of common stock from time to time in "at-the-market" offerings under the 2024 Registration Statement and related prospectus filed with the 2024 Registration Statement (the "2024 ATM Program"). During the nine months ended September 30, 2025, the Company issued and sold 1,176,449 shares of common stock at a weighted average price of $9.68 per share under the 2024 ATM Program for aggregate net sale proceeds of approximately $11.4 million after deducting sales commissions.

***Private Placement***

In March 2024, the Company entered into a subscription agreement (the "March Subscription Agreement") with GKCC, an entity controlled by a member of the Company's board of directors, providing for the issuance and sale by the Company to GKCC of pre-funded warrants (the "March 2024 Pre-Funded Warrants") (the "March 2024 Offering"). Each March 2024 Pre-Funded Warrant issued and sold in the March 2024 Offering is exercisable at an exercise price equal to $0.01 per share, subject to certain adjustments and limitations as provided under the terms of the March 2024 Pre-Funded Warrants. The net proceeds to the Company from the March 2024 Offering were approximately $6.0 million. Refer to Note 8 for additional information.

***Public Offerings***

In July 2024, the Company closed the Public Offering, which resulted in net proceeds of $10.9 million to the Company, after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company. The Public Offering consisted of the July 2024 Shares or in lieu thereof, the July 2024 Pre-Funded Warrants, and accompanying July 2024 Common Warrants. Each July 2024 Share and accompanying July 2024 Common Warrant were sold together at a combined offering price of $5.00 per July Share and accompanying July 2024 Common Warrant, and each July 2024 Pre-Funded Warrant and accompanying July 2024 Common Warrant were sold together at a combined offering price of $4.99 per July 2024 Pre-Funded Warrant and accompanying July 2024 Common Warrant, which represented the combined purchase price per July 2024 Pre-Funded Warrant and accompanying July 2024 Common Warrant less the $0.01 per share exercise price for each such July 2024 Pre-Funded Warrant.

------

<u>[**Table of Contents**](#i48b4e94dc81c43c39c91c977a31d007f_13)</u>

**ELICIO THERAPEUTICS, INC.** 

**Notes to Unaudited Interim Condensed Consolidated Financial Statements (Continued)**

The July 2024 Common Warrants have an exercise price of $5.00 per share, are immediately exercisable and will expire five years from the issuance date. Refer to Note 3 and 8 for additional information.

In January 2025, the Company entered into a securities purchase agreement with certain institutional investors (each an "Investor" and, collectively, the "Investors"), pursuant to which the Company agreed to issue and sell, in a registered direct offering by the Company directly to the Investors (the "January 2025 Offering"): (i) an aggregate of 1,261,830 shares of the Company's common stock (the "January 2025 Shares") and (ii) common warrants to purchase up to an aggregate of 1,261,830 shares of common stock (the "January 2025 Common Warrants"). Each January 2025 Share and accompanying January 2025 Common Warrant were sold together at a combined offering price of $7.925. The January 2025 Common Warrants have an exercise price of $7.80 per share, are immediately exercisable and will expire five years from the initial exercise date. The January 2025 Offering resulted in net proceeds of $9.2 million to the Company after deducting the placement agent's fees and related offering expenses. The net proceeds were allocated using the relative fair value of the January 2025 Shares and January 2025 Common Warrants.

***Senior Secured Promissory Note Financing***

In June 2025, the Company entered into a note purchase agreement (the "June 2025 Promissory Note Financing") with GKCC pursuant to which the Company issued a Senior Secured Promissory Note due June 3, 2028 (the "June 2025 Promissory Note") in the principal amount of $10.0 million. In connection with the June 2025 Promissory Note Financing, the Company issued to GKCC a warrant to purchase an aggregate of 103,225 shares of the Company's common stock (the "June 2025 Warrant"). The June 2025 Warrant has an exercise price of $7.75 per share, is immediately exercisable, and expires five years from the date of issuance. Refer to Note 11 for further detail.

**Note 7—Stock-Based Compensation**

As of September 30, 2025, there was an aggregate of 806,700 shares of common stock available for issuance under the Company's equity incentive plans, including 462,097 shares available for future grants under the Company's 2021 Incentive Award Plan, 177,295 shares available for future grants under the Company's 2022 Equity Incentive Plan, as amended, and 167,308 shares available for future grants issuance under the Company's 2024 Inducement Incentive Award Plan. Refer to Note 8 – "Stock-Based Compensation" to the Company's consolidated financial statements from the Form 10-K for the discussion of the Company's equity incentive plans.

***Stock Options***

The following table summarizes information and activity related to the Company's stock options:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Number of <br>Stock Options** | **Weighted Average <br>Exercise Price** | **Weighted Average <br>Remaining Contractual Life <br>(in years)** | **Total <br>Intrinsic Value <br>(in thousands)** |
| Outstanding as of December 31, 2024 | 1890932 | $15.69 | 6.78 | $920 |
| Options granted | 656099 | 7.40 |  |  |
| Options exercised | (31918) | 4.56 |  |  |
| Forfeited (unvested) | (51106) | 6.80 |  |  |
| Outstanding as of September 30, 2025 | 2464007 | $13.81 | 6.96 | $10525 |
| Options vested and exercisable | 1345848 | $19.92 | 5.36 | $5509 |

---

The aggregate intrinsic value in the above table is calculated as the difference between the estimated fair value of the Company's common stock and the exercise price of the stock options. 656,099 stock options were granted during the nine months ended September 30, 2025. The weighted average grant date fair value per share for the stock option grants during the nine months ended September 30, 2025 was $7.40. As of September 30, 2025, the total unrecognized compensation expense related to unvested stock option awards granted was $5.1 million, which the Company expects to recognize over a weighted-average period of approximately 2.7 years.

------

<u>[**Table of Contents**](#i48b4e94dc81c43c39c91c977a31d007f_13)</u>

**ELICIO THERAPEUTICS, INC.** 

**Notes to Unaudited Interim Condensed Consolidated Financial Statements (Continued)**

***Stock-based Compensation Expense***

The following table summarizes total stock-based compensation expense recorded in the condensed consolidated statements of operations (in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended <br>September 30,** | **Three Months Ended <br>September 30,** | **Nine Months Ended <br>September 30,** | **Nine Months Ended <br>September 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| Research and development | $264 | $138 | $755 | $414 |
| General and administrative | 434 | 176 | 1170 | 574 |
| Total | $698 | $314 | $1925 | $988 |

---

The fair value of each option is estimated on the date of grant using a Black-Scholes option pricing model with the assumptions noted in the table below. The fair value of an award with only a service condition is amortized as compensation expense on a straight-line basis over the requisite service period of the award, which is generally the vesting period. Compensation cost of awards that contain a performance condition are recognized when success is considered probable during the performance period. The Company has elected to account for forfeitures as they occur, rather than estimating the number of awards that are expected to vest. The risk-free interest rate is estimated using the weighted average rate of return on U.S. Treasury notes with a life that approximates the expected life of the option. The expected term of options granted to employees was calculated using the simplified method, which represents the average of the contractual term of the option and the weighted average vesting period of the option. The Company uses the simplified method because it does not have sufficient historical option exercise data to provide a reasonable basis upon which to estimate expected term. The contractual life of the option was used for the expected life of options granted to non-employees. Expected volatility is based on the weighted average of the historical volatility of a peer group of publicly traded companies, using the daily closing prices during the equivalent period of the calculated expected term of stock-based awards. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of the Company's common stock price becomes available, or until circumstances change, such that the identified entities are no longer comparable companies. The assumed dividend yield is based upon the Company's expectation of not paying dividends in the foreseeable future.

The fair value of each employee and non-employee stock option grant was estimated on the date of grant using Black-Scholes based on the following weighted average assumptions.

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Options** | **Three months ended September 30,** | **Three months ended September 30,** | **Nine months ended September 30,** | **Nine months ended September 30,** |
|  | **2025** | **2024** | **2025** | **2024** |
| Risk-free interest rate | 3.7% | 3.4% - 3.6% | 3.7% - 4.3% | 3.4% - 4.2% |
| Expected dividend yield | 0.0% | 0.0% | 0.0% | 0.0% |
| Expected term in years (for employees) | 6.1 | 5.8 - 6.1 | 5.5 - 6.1 | 5.0 - 6.1 |
| Expected volatility | 110.4% | 104.6% - 104.8% | 106.9% - 110.4% | 79.5% - 104.8% |

---

In March 2021 and June 2022, certain employees of the Company early exercised stock options. The shares had not fully vested at the time of exercise and were recorded as an unvested option exercise liability. As the shares vested, the Company recognized the shares and related expense as issuance of common stock upon settlement of restricted stock in the condensed consolidated financial statements for the period ended September 30, 2024.

***Employee Stock Purchase Plan***

In January 2021, the board of directors of Angion approved the Employee Stock Purchase Plan (the "ESPP"). The ESPP was effective on the date immediately prior to the effectiveness of Angion's registration statement relating to Angion's initial public offering. The offering period and purchase period was determined by Angion's board of directors. No offering periods or purchasing periods were active as of September 30, 2025. As of September 30, 2025, 275,309 shares remained available for purchase under the ESPP and no offerings have been authorized.

------

<u>[**Table of Contents**](#i48b4e94dc81c43c39c91c977a31d007f_13)</u>

**ELICIO THERAPEUTICS, INC.** 

**Notes to Unaudited Interim Condensed Consolidated Financial Statements (Continued)**

**Note 8—Warrants**

In accordance with FASB ASC Topic 815, *Derivatives and Hedging* ("ASC 815"), certain of the Company's outstanding warrants are classified as liabilities and are recorded at fair value at the issuance date, with subsequent changes in the fair value recognized in the condensed consolidated statements of operations and comprehensive loss in each reporting period. Refer to Note 3 for changes in the fair value recognized during the periods reported.

As disclosed in Note 6, in March 2024, the Company entered into the March Subscription Agreement with GKCC, an entity controlled by a member of the Company's board of directors. Each March 2024 Pre-Funded Warrant issued and sold in the March 2024 Offering is exercisable at an exercise price equal to $0.01 per share, subject to certain adjustments and limitations as provided under the terms of the March 2024 Pre-Funded Warrants.

Upon issuance, the March 2024 Pre-Funded Warrants were liability-classified, with a fair value of $6.6 million, as determined by the Black-Scholes option pricing model as of the grant date. The Company recorded the $0.6 million difference between the proceeds and grant date fair value as a loss on issuance of warrants in the statements of operations and comprehensive loss during the three months ended March 31, 2024 and nine months ended September 30, 2024. As of September 30, 2025, the March 2024 Pre-Funded Warrants were classified as equity due to the receipt of Stockholder Approval in November 2024, as discussed in Note 3.

As disclosed in Notes 3 and 6, in July 2024, the Company closed its Public Offering consisting of (i) the July 2024 Shares, (ii) the July 2024 Pre-Funded Warrants, and (iii) the July 2024 Common Warrants. Each July 2024 Pre-Funded Warrant issued and sold in the Public Offering is exercisable at an exercise price equal to $0.01 per share, subject to certain adjustments and limitations as provided under the terms of the July 2024 Pre-Funded Warrants. Each July 2024 Common Warrant is exercisable at an exercise price equal to $5.00 per share, subject to certain adjustments and limitations as provided under the terms of the July 2024 Common Warrants.

Upon issuance, the July 2024 Pre-Funded Warrants and July 2024 Common Warrants were liability-classified, with a fair value of $6.8 million and $6.5 million, respectively, measured using the Black-Scholes option pricing model as of the grant date. The Company recorded the $2.9 million difference between the proceeds and the grant date fair value as a loss on the issuance of warrants in the statements of operations and comprehensive loss during the third quarter of 2024. As of September 30, 2025, certain July 2024 Pre-Funded Warrants are classified as equity, following Stockholder Approval in November 2024. For the three and nine months ended September 30, 2025, the Company recognized a loss of $1.8 million and $3.2 million in fair value remeasurement, respectively.

Following receipt of Stockholder Approval in November 2024, the Company remeasured the March 2024 Pre-Funded Warrants and the July 2024 Pre-Funded Warrants, held by GKCC, at fair value and recognized the loss from change in fair value on the consolidated financial statements during the year ended December 31, 2024. As a result of obtaining Stockholder Approval, the March 2024 Pre-Funded Warrants and July 2024 Pre-Funded Warrants held by GKCC and its affiliates met the equity classification requirements under ASC 815. During the quarter ended December 31, 2024, the Company reclassified the July 2024 Common Warrants held by GKCC and its affiliates from liability to equity classification. The Company will re-assess the equity classification for the remaining March 2024 Pre-Funded Warrants and July 2024 Pre-Funded Warrants at each reporting period end. During the nine months ended September 30, 2025, there were no changes to the equity classification.

As disclosed in Note 6, in January 2025, the Company closed the January 2025 Offering pursuant to which the Company agreed to issue and sell: (i) the January 2025 Shares and (ii) the January 2025 Common Warrants. Each January 2025 Share and accompanying January 2025 Common Warrant were sold together at a combined offering price of $7.925. The January 2025 Common Warrants have an exercise price of $7.80 per share, are immediately exercisable and will expire five years from the initial exercise date. The fair value of the January 2025 Common Warrants, as determined by the Black-Scholes option pricing model, was $9.7 million on the closing date of the January 2025 Offering. The net proceeds were allocated using the relative fair value of the January 2025 Shares and January 2025 Common Warrants.

In June 2025, in connection with the June 2025 Promissory Note Financing, the Company issued to GKCC the June 2025 Warrant to purchase an aggregate of 103,225 shares of the Company's common stock. The June 2025 Warrant has an exercise price of $7.75 per share, is immediately exercisable and expires five years from the date of issuance. The fair value of the June 2025 Warrant, as determined by the Black-Scholes option pricing model, was $0.6 million at the date of issuance. See Note 11 for further detail regarding the June 2025 Promissory Note Financing.

------

<u>[**Table of Contents**](#i48b4e94dc81c43c39c91c977a31d007f_13)</u>

**ELICIO THERAPEUTICS, INC.** 

**Notes to Unaudited Interim Condensed Consolidated Financial Statements (Continued)**

The following tables summarize information regarding the warrants outstanding and warrant activity at September 30, 2025:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Common Stock Warrants** | **Classification** | **Number of Warrants Outstanding** | **Weighted Average Exercise Price** | **Weighted Average Remaining Contractual Life (years)** |
| Elicio Warrants | Equity-classified | 144814 | $53.59 | 3.7 |
| Angion Warrants | Liability-classified | 3950 | $76.00 | 2.9 |
| March 2024 Pre-Funded Warrants<sup>(1)</sup> | Equity-classified | 1032702 | $0.01 | Perpetual |
| July 2024 Pre-Funded Warrants<sup>(1)</sup> | Equity-classified | 1600000 | $0.01 | Perpetual |
| July 2024 Common Warrants | Liability-classified | 2041500 | $5.00 | 3.8 |
| January 2025 Common Warrants | Equity-classified | 1261830 | $7.80 | 4.3 |
| June 2025 Common Warrants | Equity-classified | 103225 | $7.75 | 4.7 |
| Total Warrants Outstanding at September 30, 2025 |  | 6188021 | 4.69 | 4.0 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<sup>(1)</sup> The March 2024 Pre-Funded Warrants and July 2024 Pre-Funded Warrants outstanding as of September 30, 2025 have a perpetual term and are therefore excluded from the calculation of the weighted-average remaining contractual life.

---

| | | | |
|:---|:---|:---|:---|
| | **Warrants** | **Weighted <br>Average <br>Exercise <br>Price** | **Weighted Average Life (years)** |
| Outstanding at December 31, 2024 | 5081466 | $3.85 | 4.5 |
| Issued | 1365055 | 7.80 |  |
| Exercised | (258500) | 5.00 |  |
| Outstanding at September 30, 2025 | 6188021 | $4.69 | 4.0 |

---

**Note 9—Commitments and Contingencies**

***Legal Proceedings***

From time to time, the Company may be involved in legal proceedings, or may be subject to various demands, claims and threatened litigation, which arise in the normal course of its business or otherwise.

The outcome of any future litigation is uncertain. Such litigation, if not resolved, could result in substantial costs to the Company, including any costs associated with the indemnification of directors and officers, and could lead to a diversion of management resources among other factors.

The Company may be exposed to litigation in connection with its products under development and operations. The Company's policy is to assess the likelihood of any adverse judgments or outcomes related to legal matters, as well as ranges of probable losses. As of the time of this report, the Company does not believe it is a party to any claim, proceeding or litigation, the outcome of which, if determined adversely to the Company, would individually or in the aggregate be reasonably expected to have a material adverse effect on its business.

------

<u>[**Table of Contents**](#i48b4e94dc81c43c39c91c977a31d007f_13)</u>

**ELICIO THERAPEUTICS, INC.** 

**Notes to Unaudited Interim Condensed Consolidated Financial Statements (Continued)**

***License Agreements***

In January 2016, Former Elicio entered into a license agreement to license certain intellectual property from a university, which agreement has been amended from time to time to license additional intellectual property and to adjust fees and milestone and diligence requirements. The Company is required to pay certain contractual maintenance and milestone payments related to clinical trials and product sales and royalties on product sales over the term of the contract, with royalty payments commencing in the calendar year of commercialization. Royalty rates range from 0.25%-2.00%, depending on whether commercial sales relate to a licensed product or an identified product, and the country the products were sold in. The license term for the license agreement extends until terminated by either party under certain provisions. During the nine months ended September 30, 2024, in accordance with the terms of the license agreement, the Company achieved a milestone related to the ongoing clinical trials and recorded license expense of $0.4 million. No such expenses were recorded in the nine months ended September 30, 2025. No commercialization royalties have been achieved to date.

The Company is required to pay a total of up to $20.9 million upon achievement of certain late-stage developmental and commercial milestones. The developmental milestone payments will be recorded when each milestone is achieved, and the commercial milestone payments and royalties will be recorded when the sales occur.

Future minimum annual maintenance payments are $0.1 million for the year ended December 31, 2025 and for each year thereafter. Future minimum annual payments are due until the termination of the agreement.

**Note 10—Leases**

***Operating Leases***

The Company has an operating lease for office and laboratory space in Boston, Massachusetts (the "Boston Lease"). The Boston Lease commenced in February 2022 with the term set to expire in February 2030. The Boston Lease has rent payments escalating annually, which total $11.1 million in the aggregate. As a result, at the commencement of the Boston Lease the Company recognized a right-of-use ("ROU") lease asset of $8.0 million with a corresponding lease liability of $8.0 million based on the present value of the minimum rental payments. In addition, the Company will make payments for operating expenses and real estate taxes. In June 2023, the Company secured a letter of credit for the $0.7 million deposit on the Boston Lease, which was reported as restricted cash, noncurrent on the condensed consolidated balance sheets as of September 30, 2025 and December 31, 2024.

The Company also assumed a lease for clinical and regulatory space in Newton, Massachusetts, comprising approximately 6,157 square feet for approximately $0.2 million per year, under a non-cancelable operating lease that expired on June 30, 2024.

Lease expense for all leases for the three and nine months ended September 30, 2025 was $0.3 million and $1.0 million, respectively. Lease expense for all leases for the three and nine months ended September 30, 2024 was $0.3 million and $1.1 million, respectively.

The following table summarizes quantitative information about the Company's operating leases (dollars in thousands):

---

| | | |
|:---|:---|:---|
| | **Nine Months Ended <br>September 30,** | **Nine Months Ended <br>September 30,** |
| | **2025** | **2024** |
| Operating cash outflows from operating leases | $1012 | $1096 |
| Weighted-average remaining lease term—operating leases (in years) | 4.3 | 5.3 |
| Weighted-average discount rate—operating leases | 8.0% | 8.0% |

---

------

<u>[**Table of Contents**](#i48b4e94dc81c43c39c91c977a31d007f_13)</u>

**ELICIO THERAPEUTICS, INC.** 

**Notes to Unaudited Interim Condensed Consolidated Financial Statements (Continued)**

As of September 30, 2025, maturities of lease liabilities were as follows (in thousands):

---

| | |
|:---|:---|
| **Year Ended December 31,** | **Amounts** |
| 2025 (remaining three months) | $338 |
| 2026 | 1383 |
| 2027 | 1425 |
| 2028 | 1467 |
| 2029 | 1512 |
| Thereafter | 253 |
| Total | 6378 |
| Less present value discount | (1041) |
| Operating lease liabilities | 5337 |
| Less: operating lease liability, current portion | (981) |
| Operating lease liability, noncurrent portion | $4356 |

---

**Note 11 - Debt**

***Senior Secured Convertible Note Financing***

In August 2024, the Company entered into a securities purchase agreement (the "Securities Purchase Agreement") with GKCC, an entity controlled by a member of the Company's board of directors, pursuant to which the Company issued a 3% Senior Secured Convertible Promissory Note due February 15, 2026 (the "Convertible Note") in the principal amount of $20.0 million (the "Convertible Note Financing"). Unless earlier converted in accordance with the terms of the Convertible Note, the Convertible Note would mature on February 15, 2026. Interest on the Convertible Note accrued and was payable quarterly in cash on the principal amount equal to 3% per annum, with an initial interest payment date of June 30, 2025.

The Company received net proceeds of approximately $19.7 million from the Convertible Note Financing, after deducting debt issuance costs.

The Convertible Note included multiple conversion features. The Company evaluated all conversion features included within the Convertible Note, under ASC 815*,* and determined that the default interest feature met the definition of a derivative, but the value was de minimis. During the nine months ended September 30, 2025, the Company recorded an immaterial amount in other expense related to the accretion of the discount of Convertible Note debt issuance costs. During the nine months ended September 30, 2025, the Company recorded accrued interest expense of $0.1 million related to the interest due on the Convertible Note but not yet payable.

In March 2025, the Company exercised its right under the Convertible Note to require GKCC to convert the full amount of the Convertible Note, including all accrued and unpaid interest, into shares of the Company's common stock. In March 2025, the Company issued 3,500,573 shares of its common stock to GKCC in exchange for the principal balance of $20.0 million plus $0.3 million in accrued interest, in satisfaction in full of the Convertible Note.

***Senior Secured Promissory Note Financing***

In June 2025, the Company issued the June 2025 Promissory Note in the principal amount of $10.0 million to GKCC, an entity controlled by a member of the board of directors of the Company. The June 2025 Promissory Note will mature on June 3, 2028, or such earlier date as the June 2025 Promissory Note is required or permitted to be repaid in accordance with the terms of the June 2025 Promissory Note and is a senior, secured obligation of the Company and its subsidiaries. Interest will accrue and be payable in cash on the principal amount at the rate of the sum of the Prime Rate (as defined in the June 2025 Promissory Note) plus 5.00%, provided that the maximum interest rate shall not exceed 12.5% per annum, with an initial interest payment date of July 1, 2026. The June 2025 Promissory Note is secured by a (i) first priority lien on substantially all assets of the Company and its subsidiaries, pursuant to a security agreement and (ii) first priority lien on intellectual property of the Company, pursuant to an intellectual property security agreement. The June 2025 Promissory Note contains customary terms and covenants and customary events of default.

------

<u>[**Table of Contents**](#i48b4e94dc81c43c39c91c977a31d007f_13)</u>

**ELICIO THERAPEUTICS, INC.** 

**Notes to Unaudited Interim Condensed Consolidated Financial Statements (Continued)**

Additionally, in connection with the June 2025 Promissory Note Financing, the Company issued to GKCC the June 2025 Warrant to purchase an aggregate of 103,225 shares of the Company's common stock. The June 2025 Warrant has an exercise price of $7.75 per share, is immediately exercisable and expires five years from the date of issuance. GKCC will not have the right to exercise any portion of the June 2025 Warrant if GKCC (together with its affiliates) would beneficially own in excess of 49.99% of the number of shares of the Company's common stock outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the June 2025 Warrant. The fair value of the June 2025 Warrants, as determined by the Black-Scholes option pricing model, was $0.6 million at the date of issuance, and recorded as a debt discount to the June 2025 Promissory Note.

The Company received net proceeds of $9.9 million from the sale of the June 2025 Promissory Note, after deducting debt issuance costs. The June 2025 Promissory Note included multiple conversion features. The Company evaluated all conversion features included within the June 2025 Promissory Note, under ASC 815*,* and determined that the default interest feature met the definition of a derivative, but the value was immaterial. The net proceeds were allocated with the June 2025 Warrant using the relative fair value. As of September 30, the net carrying value of the June 2025 Promissory Note was $9.7 million and the debt discount for the June 2025 Promissory Note was $0.3 million. Accretion of the discount on the June 2025 Promissory Note was $0.4 million and $0.5 million for the three and nine months ended September 30, 2025, respectively.

**Note 12—Income Taxes**

The Company did not record a provision or benefit for income taxes during the three and nine months ended September 30, 2025 or 2024. As of September 30, 2025 and December 31, 2024, the Company continues to maintain a full valuation allowance against all of its deferred tax assets in light of its history of cumulative net losses.

On July 4, 2025, H.R. 1 (the "Act"), formerly known as the One Big Beautiful Bill Act, was signed into law in the United States, introducing changes to U.S. federal tax provisions affecting businesses. The Act includes modifications to the capitalization of research and development expenses and to the depreciation of fixed assets. The legislation has multiple effective dates, with certain provisions effective in 2025 and others implemented through 2027. The Company is currently evaluating the full impact of the Act on its financial position, results of operations, and cash flows. However, the Company does not expect the Act to have a material effect on its financial statements. The impact to the Company's income tax expense and effective tax rate for the three and nine months ended September 30, 2025 associated with this legislation is not material.

**Note 13—Net Loss Per Share**

The Company has reported losses since inception and has computed basic net loss per share attributable to common stockholders by dividing net loss attributable to common stockholders by the weighted-average number of shares of common stock and pre-funded warrants outstanding for the period, without consideration for potentially dilutive securities. The Company computes diluted net loss per share of common stock after giving consideration to all potentially dilutive shares of common stock, including options to purchase common stock and preferred stock outstanding during the period determined using the treasury-stock and if-converted methods, except where the effect of including such securities would be anti-dilutive. Because the Company has reported net losses since inception, these potential shares of common stock and preferred stock have been anti-dilutive and basic and diluted loss per share were the same for all periods presented.

Basic and diluted net loss per share attributable to common stockholders was calculated for the three and nine months ended September 30, 2025 and 2024 as follows (in thousands, except share and per share data):

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended <br>September 30,** | **Three Months Ended <br>September 30,** | **Nine Months Ended <br>September 30,** | **Nine Months Ended <br>September 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| **Numerator** |  |  |  |  |
| Net loss | $(10083) | $(18838) | $(31853) | $(37894) |
| **Denominator:** |  |  |  |  |
| Weighted average of common shares and pre-funded warrants outstanding, basic and diluted | 16692476 | 13582345 | 15247864 | 11720527 |
| Net loss per share, basic and diluted | $(0.60) | $(1.39) | $(2.09) | $(3.23) |

---

------

<u>[**Table of Contents**](#i48b4e94dc81c43c39c91c977a31d007f_13)</u>

**ELICIO THERAPEUTICS, INC.** 

**Notes to Unaudited Interim Condensed Consolidated Financial Statements (Continued)**

The table below provides potentially dilutive securities not included in the calculation of the diluted net loss per share because to do so would be anti-dilutive:

---

| | | |
|:---|:---|:---|
| | **Nine Months Ended <br>September 30,** | **Nine Months Ended <br>September 30,** |
| | **2025** | **2024** |
| Shares issuable upon exercise of stock options | 2464007 | 819302 |
| Shares issuable upon the exercise of warrants (excluding pre-funded warrants) | 3555319 | 2448769 |
| Total | 6019326 | 3268071 |

---

**Note 14 —Related Party Transactions** 

***Private Placement and Subscription Agreement***

In March 2024, the Company entered into the March Subscription Agreement with GKCC, an entity controlled by a member of the Company's board of directors. Each March 2024 Pre-Funded Warrant issued and sold in the March 2024 Offering is exercisable at an exercise price equal to $0.01 per share, subject to certain adjustments and limitations as provided under the terms of the March 2024 Pre-Funded Warrants.

The net proceeds to the Company from the March 2024 Offering were approximately $6.0 million.

***Public Offering***

As part of the Public Offering described in Note 6, Yekaterina Chudnovsky, a member of the Company's board of directors, and Jay Venkatesan, a member of the Company's board of directors, and trusts affiliated with Jay Venkatesan, purchased 1,600,000 July 2024 Pre-Funded Warrants and accompanying July 2024 Common Warrants and 200,000 July 2024 Pre-Funded Warrants and accompanying July 2024 Common Warrants, respectively, with such July 2024 Pre-Funded Warrants and July 2024 Common Warrants subject to the terms and conditions of the July 2024 Pre-Funded Warrants and July 2024 Common Warrants.

The net proceeds to the Company from the Public Offering were approximately $10.9 million.

***Senior Secured Convertible Note Financing***

In August 2024, the Company entered into the Securities Purchase Agreement with GKCC, pursuant to which the Company issued the Convertible Note in the principal amount of $20.0 million. The Company received net proceeds of approximately $19.7 million from the Convertible Note Financing, after deducting debt issuance costs.

In March 2025, the Company exercised its right under the Convertible Note to require GKCC to convert the full amount of the Convertible Note, including all accrued and unpaid interest, into shares of the Company's common stock. The Company issued 3,500,573 shares of its common stock to GKCC in exchange for the principal balance of $20.0 million plus $0.3 million in accrued interest, in satisfaction in full of the Convertible Note.

***Senior Secured Promissory Note Financing***

In June 2025, the Company entered into the June 2025 Promissory Note Financing with GKCC, pursuant to which the Company issued the June 2025 Promissory Note in the principal amount of $10.0 million. The Company received net proceeds of approximately $9.9 million from the June 2025 Promissory Note Financing, after deducting debt issuance costs.

Additionally, in connection with the June 2025 Promissory Note Financing, the Company issued to GKCC the June 2025 Warrant to purchase an aggregate of 103,225 shares of the Company's common stock.

------

<u>[**Table of Contents**](#i48b4e94dc81c43c39c91c977a31d007f_13)</u>

**ELICIO THERAPEUTICS, INC.** 

**Notes to Unaudited Interim Condensed Consolidated Financial Statements (Continued)**

**Note 15 - Segment Reporting**

The Company has one reportable segment relating to the development of immunotherapies for patients with limited treatment options and poor outcomes suffering from cancer. The Company's Chief Operating Decision Maker ("CODM"), its Chief Executive Officer, manages the Company's operations on a consolidated basis, assesses performance for the operating segment and decides how to allocate resources based on consolidated net loss, which is reported on the condensed consolidated statements of operations and comprehensive loss. Depreciation expense, amortization expense, stock-based compensation expense, and the change in fair value of warrants are significant noncash items included in consolidated net loss reviewed by the CODM and are reported on the condensed consolidated statements of cash flows. Other segment items include interest income, interest expense, grant income, and change in the fair value of liability-classified warrants. Expenditures for additions to long-lived assets, which include purchases of property and equipment, are included in total consolidated assets reviewed by the CODM and are reported on the condensed consolidated statements of cash flows. All long-lived assets are located in the United States. The following table presents certain financial data for the Company's reportable segment (in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three months ended September 30,** | **Three months ended September 30,** | **Nine months ended September 30,** | **Nine months ended September 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| Clinical trial expenses | $1054 | $3757 | $8491 | $9304 |
| Employee related research and development expenses | 2073 | 1995 | 6696 | 6147 |
| Chemistry, manufacturing and controls expenses | 456 | 476 | 1486 | 3534 |
| Other research and development expenses | 1458 | 1523 | 3909 | 4849 |
| Contract and grant reimbursements |  | (544) | (754) | (888) |
| Employee related general and administrative expenses | 1333 | 846 | 3782 | 2724 |
| Professional fees and other general and administrative expenses | 1670 | 2289 | 5259 | 5837 |
| Other segment items | 2039 | 8496 | 2984 | 6387 |
| Segment net loss | $10083 | $18838 | $31853 | $37894 |

---

---

| | | |
|:---|:---|:---|
| | **September 30,<br>2025** | **December 31,<br>2024** |
| Total segment assets | $28284 | $28178 |

---

------

<u>[**Table of Contents**](#i48b4e94dc81c43c39c91c977a31d007f_13)</u> 

**Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations**

*You should read the following discussion and analysis of our financial condition and results of operations together with our condensed consolidated financial statements and the related notes appearing elsewhere in this Quarterly Report on Form 10-Q and in our audited financial statements and accompanying notes for the years ended December 31, 2024 and 2023 included in the Form 10-K. In addition to the historical financial information, this discussion contains forward-looking statements that involve risks, assumptions and uncertainties, such as statements of our plans, objectives, expectations, intentions, forecasts and projections. Our actual results and the timing of selected events could differ materially from those discussed in these forward-looking statements as a result of several factors, including those set forth under the sections titled "Risk Factors" in this Quarterly Report on Form 10-Q, the Quarterly Reports for the quarters ended March 31, 2025 and June 30, 2025, and the Form 10-K, which you should read carefully to gain an understanding of the important factors that could cause actual results to differ materially from our forward-looking statements. Please also see the section titled* "*Forward-Looking Statements*" *at the beginning of this report.*

**Overview**

We are a clinical-stage biotechnology company pioneering the development of immunotherapies for patients with limited treatment options and poor outcomes suffering from cancer. Our proprietary Amphiphile ("AMP") technology is designed to generate robust anti-tumor T lymphocytes ("T cell") responses by preferentially targeting lymph nodes. Recent advances have identified T cell responses as a key component of effective cancer immunotherapy and we believe our AMP technology can generate a robust T cell response that can potentially provide meaningful clinical benefit.

We believe the therapeutic utility of currently approved and development stage cancer immunotherapies are limited in many cases due to their inability to sufficiently localize to lymph nodes and adequately engage with the critical immune cells responsible for stimulating adaptive immunity. Our AMP technology is specifically intended to localize payloads to lymph nodes leading to the generation of a robust T cell response that we believe is critical to generate an anticancer immune response.

Our lead programs focus on our cancer immunotherapy product candidates, which target biologically validated driver tumor mutations using common and well characterized neoantigens. This strategy results in an "off-the-shelf" therapeutic option allowing patients to receive treatment without delayed manufacturing timelines and increased costs associated with personalized immunotherapy approaches.

Our clinical pipeline includes the lymph node targeted therapeutic cancer immunotherapy ELI-002 7P, currently being evaluated in a Phase 2 study, designed to stimulate an immune response against mutant KRAS ("mKRAS") pancreatic ductal adenocarcinoma ("PDAC"), the most common form of pancreatic cancer. The ELI-002 7P formulation is designed to provide immune response coverage against seven KRAS mutations in 88% of PDAC patients and 25% of all solid tumors, thereby increasing the potential patient population for ELI-002 7P. In August 2025, we announced that following the Independent Data Monitoring Committee's ("IDMC") pre-specified interim review of unblinded safety and efficacy data in our Phase 2 AMPLIFY-7P study in mKRAS-driven PDAC, the IDMC recommended that the trial continue to the final analysis without modifications. In addition, the IDMC confirmed the favorable safety profile of ELI-002 7P to date. We anticipate the final disease-free survival analysis to occur in the first half of 2026. ELI-002 2P (2-peptide formulation) has been studied previously in the Phase 1 (AMPLIFY-201) trial in patients with high relapse risk mKRAS-driven solid tumors, following surgery and chemotherapy. Our preclinical pipeline includes the lymph node targeted therapeutic immunotherapies ELI-007, currently being evaluated in preclinical studies for the treatment of mutant b-raf murine sarcoma viral oncogene homolog B1-driven cancers, and ELI-008, currently being evaluated in preclinical studies for use in the treatment of mutated tumor protein p53 expressing cancers. We believe that each of our immunotherapy product candidates, if approved, has the potential to reduce the risk of recurrence of tumors carrying specific oncogenic driver mutations.

Our operations to date have been financed primarily by aggregate net proceeds of $214.8 million from the issuance of common stock, pre-funded warrants, convertible preferred stock, convertible notes, promissory notes, the exercise of stock options and common warrants, the private placement of our securities, at-the-market offerings, and proceeds from the Merger with Angion. Since inception, we have had significant annual operating losses. Our net loss was $10.1 million and $31.9 million for the three and nine months ended September 30, 2025, respectively, and $18.8 million and $37.9 million for the three and nine months ended September 30, 2024, respectively. As of September 30, 2025, we had an accumulated deficit of $226.0 million and $20.6 million in cash and cash equivalents.

------

<u>[**Table of Contents**](#i48b4e94dc81c43c39c91c977a31d007f_13)</u> 

We are currently facing substantial doubt about our ability to continue as a going concern, given our cash position and cash runway. As of the filing date of this Quarterly Report on Form 10-Q, we believe that our cash on hand will enable us to fund our operations through the second quarter of 2026 based on our current financial operating plan. This period could be shortened or lengthened if there are any significant increases or decreases in planned or actual spending on development programs or more rapid progress of development programs than anticipated. There is no assurance that financing will be available when needed to allow us to continue as a going concern. Our losses from operations, negative operating cash flows and accumulated deficit, as well as the additional capital needed to fund operations for at least twelve months following the issuance of the condensed consolidated financial statements, raise substantial doubt about our ability to continue as a going concern. We expect to incur substantial expenditures in the foreseeable future for the development of our product candidates and will require additional financing to continue this development. We plan to address this condition through the sale of common stock or other securities in public offerings and/or private placements, debt financings, or through other capital sources, including licensing arrangements, partnerships and collaborations with other companies or other strategic transactions, but there is no assurance these plans will be completed successfully or at all. If we are unable to obtain additional capital when and as needed to continue as a going concern, we might have to further reduce or scale back our operations and/or liquidate our assets, and the values we receive for our assets in liquidation or dissolution could be significantly lower than the values reflected in our financial statements.

Our condensed consolidated financial statements appearing elsewhere in this Quarterly Report on Form 10-Q have been prepared on a basis that assumes that we will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. Our condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern.

Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our accounts payable and accrued expenses. We expect to continue to incur net losses for the foreseeable future, and we expect our research and development expenses, general and administrative expenses, and capital expenditures will continue to increase. In particular, we expect our expenses to increase as we continue our development of, and seek regulatory approvals for, our product candidates, as well as hire additional personnel, pay fees to outside consultants, attorneys and accountants, and incur other increased costs associated with being a public company. In addition, if and when we seek and obtain regulatory approval to commercialize any product candidate, we will also incur increased expenses in connection with commercialization and marketing of any such product. Our net losses may fluctuate significantly from quarter-to-quarter and year-to-year, depending on the timing of our clinical trials and our expenditures on other research and development activities. We anticipate that our expenses will increase significantly in connection with our ongoing activities, as we:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• advance our lead product candidate, ELI-002 7P, to late stage clinical trials;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• advance our preclinical programs to clinical trials;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• expand our pipeline of product candidates;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• seek regulatory approval for our investigational medicines;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• maintain, expand, protect and defend our intellectual property portfolio;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• acquire or in-license technology;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• expand our clinical, scientific, management and administrative teams; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• operate as a public company.

As of the filing date of this Quarterly Report on Form 10-Q, we believe that our cash on hand will enable us to fund our operations through the second quarter of 2026 based on our current plan. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. To finance our operations beyond that point we will need to raise additional capital, which cannot be assured. Our losses from operations, negative operating cash flows and accumulated deficit, as well as the additional capital needed to fund operations for at least twelve months following the issuance of the condensed consolidated financial statements, raise substantial doubt about our ability to continue as a going concern.

------

<u>[**Table of Contents**](#i48b4e94dc81c43c39c91c977a31d007f_13)</u> 

We have not had any products approved for sale. We do not expect to generate any product sales unless and until we successfully complete development and obtain regulatory approval for one or more of our product candidates. If we obtain regulatory approval for any of our product candidates, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution. As a result, until such time, if ever, that we can generate substantial product revenue, we expect to finance our cash needs through equity offerings, debt financings or other capital sources, including collaborations, licenses or similar arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed or on favorable terms, if at all. Any failure to raise capital as and when needed could have a negative impact on our financial condition and on our ability to pursue our business plans and strategies, including our research and development activities. If we are unable to raise capital, we will need to delay, reduce or terminate planned activities to reduce costs.

**Components of Results of Operations**

The following discussion summarizes the key factors our management believes are necessary for an understanding of our financial statements.

***Operating Expenses***

Our operating expenses since inception have consisted primarily of research and development expenses and general and administrative costs.

*Research and Development Expenses*

Our research and development expenses consist primarily of costs incurred for the development of our product candidates and our drug discovery efforts, which include:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• personnel costs, which include salaries, benefits, and equity-based compensation expense;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• expenses incurred under agreements with consultants and contract organizations that conduct research and development activities on our behalf;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• costs related to sponsored research service agreements;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• costs related to production of preclinical and clinical materials, including fees paid to contract manufacturers;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• laboratory and vendor expenses related to the execution of preclinical studies and planned clinical trials; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• laboratory supplies and equipment used for internal research and development activities.

We expense all research and development costs in the periods in which they are incurred. Costs for certain research and development activities are recognized based on an evaluation of the progress to completion of specific tasks using information and data provided to us by our vendors and service providers.

Our research and development expenses are not currently tracked on a program-by-program basis. We use our personnel and infrastructure resources across multiple research and development programs directed toward identifying and developing product candidates. Substantially all our research and development costs are incurred on the development of ELI-002 7P and our preclinical candidates.

We expect our research and development expenses to increase substantially for the foreseeable future as we continue to invest in research and development activities related to developing our product candidates, including investments in conducting clinical trials, manufacturing and otherwise advancing our programs. The process of conducting the clinical research necessary to obtain regulatory approval is costly and time-consuming, and the successful development of our product candidates is highly uncertain. At this time, we cannot reasonably estimate the nature, timing and costs of the efforts that will be needed to complete the development of, or the period, if any, in which material net cash inflows may commence from ELI-002 7P or any of our preclinical candidates. This is due to the numerous risks and uncertainties associated with developing drugs, including the uncertainty of:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the scope, rate of progress and expense of our research and development activities;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• clinical trials and early-stage results;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the terms and timing of regulatory approvals; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the ability to market, commercialize and achieve market acceptance for ELI-002 7P, or any of our preclinical candidates that we or our future collaboration partners may develop in the future.

------

<u>[**Table of Contents**](#i48b4e94dc81c43c39c91c977a31d007f_13)</u> 

Any of these variables with respect to the development of ELI-002 7P, or any other of our preclinical candidates that we may develop could result in a significant change in the costs and timing associated with the development of such candidates. For example, if the FDA or other regulatory authority were to require us to conduct preclinical and clinical studies beyond those which we currently anticipate will be required for the completion of clinical development or if we experience significant delays in enrollment in any clinical trials, we could be required to expend significant additional financial resources and time on the completion of our clinical development programs.

*General and Administrative Expenses*

Our general and administrative expenses consist primarily of personnel costs, including equity-based compensation, and other expenses for outside professional services, including marketing, legal, audit and accounting, facility-related costs not otherwise included in research and development expenses, and recruiting. We expect our general and administrative expenses to increase over the next several years to support our continued research and development activities, manufacturing activities, increased costs of expanding our operations and operating as a public company. These increases will likely include increases related to the hiring of additional personnel and legal, regulatory and other fees and services associated with maintaining compliance with the Nasdaq Marketplace Rules or the Nasdaq Listing Rules and SEC requirements, accounting and audit fees, director and officer insurance costs and investor relations costs associated with being a public company.

***Other (Expense) Income***

For the three and nine months ended September 30, 2025 and 2024, other income and expense consisted primarily of interest income, foreign exchange transaction gains and losses, gain on sale of equipment, interest expense, gains and losses related to the re-measurement of our warrant liabilities, and a loss on issuance of the July 2024 Pre-Funded Warrants.

**Results of Operations**

***Comparison of the Three Months Ended September 30, 2025 and 2024***

The following table summarizes our results of operations for the periods indicated (in thousands, except percentages):

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended <br>September 30,** | **Three Months Ended <br>September 30,** | | |
| | **2025** | **2024** |<br>**$ Change** |<br>**% Change** |
| **Operating expenses:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Research and development | $5039 | $7208 | $(2169) | (30)% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;General and administrative | 3006 | 3136 | (130) | (4)% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total operating expenses | 8045 | 10344 | (2299) | (22)% |
| **Loss from operations** | (8045) | (10344) | 2299 | (22)% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total other (expense), net | (2038) | (8494) | 6456 | (76)% |
| **Net loss** | $**(10083)** | $**(18838)** | $8755 | (46)% |

---

*Research and Development Expenses*

Research and development expenses were $5.0 million for the three months ended September 30, 2025, compared to $7.2 million for the three months ended September 30, 2024. The decrease of $2.2 million was primarily due to less clinical trial costs as patients progressed through the Phase 2 study of ELI-002 7P.

*General and Administrative Expenses*

General and administrative expenses were $3.0 million for the three months ended September 30, 2025, compared to $3.1 million for the three months ended September 30, 2024. The decrease of $0.1 million was primarily due to lower professional fees incurred in connection with general corporate matters.

------

<u>[**Table of Contents**](#i48b4e94dc81c43c39c91c977a31d007f_13)</u> 

*Other (Expense) Income*

Other (expense) income for the three months ended September 30, 2025 was $(2.0) million compared to $(8.5) million for the three months ended September 30, 2024. The decrease of $6.5 million was primarily due to the change in fair value associated with the outstanding liability-classified common warrants, and the initial loss recognized from the Public Offering, including losses from the July 2024 Pre-Funded Warrants and July 2024 Common Warrants.

**Results of Operations**

***Comparison of the Nine Months Ended September 30, 2025 and 2024***

The following table summarizes our results of operations for the periods indicated (in thousands, except percentages):

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Nine Months Ended <br>September 30,** | **Nine Months Ended <br>September 30,** | | |
| | **2025** | **2024** |<br>**$ Change** |<br>**% Change** |
| **Operating expenses:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Research and development | $19823 | $22947 | $(3124) | (14)% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;General and administrative | 9049 | 8563 | 486 | 6% |
| Total operating expenses | 28872 | 31510 | (2638) | (8)% |
| **Loss from operations** | (28872) | (31510) | 2638 | (8)% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other (expense), net | (2981) | (6384) | 3403 | (53)% |
| **Net loss** | $**(31853)** | $**(37894)** | $6041 | (16)% |

---

*Research and Development Expenses*

Research and development expenses were $19.8 million for the nine months ended September 30, 2025, compared to $22.9 million for the nine months ended September 30, 2024. The decrease of $3.1 million was primarily due to lower costs as patients progressed through the Phase 2 study of ELI-002 7P.

*General and Administrative Expenses*

General and administrative expenses were $9.0 million for the nine months ended September 30, 2025, compared to $8.6 million for the nine months ended September 30, 2024. The increase of $0.5 million was primarily due to the external costs associated with the January 2025 Offering and June 2025 Promissory Note Financing.

*Other (Expense) Income*

Other (expense) income for the nine months ended September 30, 2025 was $(3.0) million compared to $(6.4) million for the nine months ended September 30, 2024. The decrease of $3.4 million was primarily due to the change in fair value associated with the outstanding liability-classified common warrants, and the losses recognized from the March 2024 Offering and the Public Offering.

**Liquidity and Capital Resources**

***Sources and Uses of Liquidity***

Our operations through September 30, 2025 have been financed primarily by aggregate net proceeds of $214.8 million from the issuance of common stock, pre-funded warrants, convertible preferred stock, convertible notes, promissory notes, the exercise of stock options and common warrants, the private placement of our securities, at-the-market offerings, and proceeds from the Merger with Angion. Since inception, we have had significant operating losses. Our net loss was $31.9 million and $37.9 million for the nine months ended September 30, 2025 and 2024, respectively. As of September 30, 2025, we had an accumulated deficit of $226.0 million and $20.6 million in cash and cash equivalents. Our primary use of cash is to fund operating expenses, which consist primarily of research and development expenditures, and to a lesser extent, general and administrative expenditures. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable and accrued expenses.

------

<u>[**Table of Contents**](#i48b4e94dc81c43c39c91c977a31d007f_13)</u> 

Our losses from operations, negative operating cash flows and accumulated deficit, as well as the additional capital needed to fund operations for at least twelve months following the issuance of the condensed consolidated financial statements, raise substantial doubt about our ability to continue as a going concern. We expect to incur substantial expenditures in the foreseeable future for the development of our product candidates and will require additional financing to continue this development. The unaudited condensed consolidated financial statements appearing elsewhere in this Quarterly Report on Form 10-Q have been prepared on a basis that assumes that we will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The unaudited condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern. We plan to address this condition through the sale of common stock or other securities in public offerings and/or private placements, debt financings, or through other capital sources, including licensing arrangements, partnerships and collaborations with other companies or other strategic transactions. However, there is no assurance that we will be successful in raising additional capital or that such additional funds will be available on acceptable terms, if at all. Should we be unable to raise this amount of capital our operating plans will be limited to the amount of capital that we can access. We may also consider steps to reduce our operating expenses. There can be no assurances that we will be successful in any of the foregoing.

***Summary Statement of Cash Flows***

The following table sets forth a summary of our net cash flow activity for the nine months ended September 30, 2025 and 2024 (in thousands):

---

| | | |
|:---|:---|:---|
| | **Nine Months Ended <br>September 30,** | **Nine Months Ended <br>September 30,** |
| | **2025** | **2024** |
| Net cash provided by (used in) |  |  |
| &nbsp;&nbsp;&nbsp;Operating activities | $(30155) | $(28324) |
| &nbsp;&nbsp;&nbsp;Investing activities |  | (39) |
| &nbsp;&nbsp;&nbsp;Financing activities | 31832 | 42094 |
| &nbsp;&nbsp;&nbsp;Effect of foreign currency on cash | 144 | (5) |
| Net increase in cash | $1821 | $13726 |

---

*Operating Activities*

For the nine months ended September 30, 2025, net cash (used in) operating activities was $(30.2) million, which consisted of a net loss of $31.9 million, changes in our assets and liabilities of $4.9 million, and non-cash charges of $6.6 million. The non-cash charges were related to $3.2 million of change in the fair value of warrant liabilities, $1.9 million of stock-based compensation, $0.7 million amortization of the ROU asset, $0.2 million depreciation and $0.6 million of non-cash interest expense.

For the nine months ended September 30, 2024, net cash (used in) operating activities was $(28.3) million, which consisted of a net loss of $37.9 million and changes in our assets and liabilities of $0.3 million and non-cash charges of $9.3 million. The non-cash charges were primarily related to $3.3 million of change in the fair value of warrant liabilities, $3.5 million loss on the issuance of the March 2024 Pre-Funded Warrants in the March 2024 Offering, $1.0 million of stock-based compensation, $0.6 million amortization of the ROU asset, $0.5 million related to issuance costs for the July 2024 Pre-Funded Warrants and July 2024 Common Warrants, $0.1 million of non-cash interest expense, and $0.2 million of depreciation.

*Investing Activities*

For the nine months ended September 30, 2025 and 2024, net cash provided by or used in investing activities was immaterial.

*Financing Activities*

For the nine months ended September 30, 2025, net cash provided by financing activities was $31.8 million as a result of the issuance of $11.4 million of our common stock under our at-the-market offering program with JonesTrading Institutional Services LLC, as sales agent, $9.1 million from the January 2025 Offering, $9.9 million from the June 2025 Promissory Note Financing, $1.3 million from the exercise of common warrants and $0.1 million from the exercise of stock options.

------

<u>[**Table of Contents**](#i48b4e94dc81c43c39c91c977a31d007f_13)</u> 

For the nine months ended September 30, 2024, net cash provided by financing activities was $42.1 million, primarily as a result of the issuance of the convertible note for $19.7 million, $10.9 million from the Public Offering, $6.0 million from the issuance of the March 2024 Pre-Funded Warrants in the March 2024 Offering, and the issuance of $5.4 million of our common stock under our at-the-market offering program with Stifel, Nicolaus & Company, Incorporated and Virtu Americas LLC, as sales agents.

***Future Cash Needs and Funding Requirements***

Based on our current operating plan, as of the filing date of this Quarterly Report on Form 10-Q, we believe our cash and cash equivalents will be sufficient to fund our planned operations through the second quarter of 2026. However, we have based our projections of operating capital requirements on assumptions that may prove to be incorrect and we may use all our available capital resources sooner than we expect. We are unable to estimate the exact amount of our operating capital requirements. The amount and timing of our future funding requirements will depend on many factors, including, but not limited to:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;▪ the scope, progress, results and costs of researching and developing product candidates, and conducting preclinical studies and clinical trials;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;▪ the outcome of any future clinical trials, for any existing or future product candidates;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;▪ whether we are able to take advantage of any FDA expedited development and approval programs for any of our product candidates;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;▪ the outcome, costs and timing of seeking and obtaining and maintaining FDA and any foreign regulatory approvals;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;▪ the costs associated with any delays we may encounter as a result of evolving regulatory requirements or adverse results with respect to any of our product candidates;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;▪ the number and characteristics of product candidates we pursue, including product candidates in preclinical development;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;▪ the ability of our product candidates to progress through clinical development successfully;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;▪ our need to expand our research and development activities, including to conduct additional clinical trials;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;▪ market acceptance of our product candidates, including physician adoption, market access, pricing and reimbursement;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;▪ the costs of acquiring, licensing or investing in businesses, products, product candidates and technologies;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;▪ our ability to maintain, expand and defend the scope of our intellectual property portfolio, including the amount and timing of any payments potentially required to make, or that we may receive, in connection with the licensing, filing, prosecution, defense and enforcement of any patents or other intellectual property rights;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;▪ our need and ability to hire additional personnel, including management, clinical development, medical and commercial personnel;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;▪ the effect of competing technological, market developments and government policy;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;▪ the costs associated with being a public company, including our need to implement additional internal systems and infrastructure, including financial and reporting systems;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;▪ the costs associated with securing and establishing commercialization and manufacturing capabilities, as well as those associated with packaging, warehousing and distribution;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;▪ the economic and other terms, timing of and success of our existing licensing arrangements and any collaboration, licensing or other arrangements into which we may enter in the future and timing and amount of payments thereunder; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;▪ the timing, receipt and amount of sales and general commercial success of any future approved products, if any.

------

<u>[**Table of Contents**](#i48b4e94dc81c43c39c91c977a31d007f_13)</u> 

Until such time as we can generate significant revenue from sales of product candidates, if ever, we expect to finance our operations through the sale of common stock or other securities in public offerings and/or private placements, debt financings, or through other capital sources, including licensing arrangements, partnerships and collaborations with other companies or other strategic transactions. Adequate funding may not be available to us on acceptable terms, or at all. To the extent we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be or could be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing and equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise funds through additional collaborations, or other similar arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to and/or may reduce the value of our common stock. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or commercialization efforts or grant rights to develop and market our product candidates even if we would otherwise prefer to develop and market such product candidates ourselves.

**Critical Accounting Policies and Significant Judgments and Estimates**

Our management's discussion and analysis of our financial condition and results of operations is based on our condensed consolidated financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these condensed consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, as well as the reported expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

Our critical accounting policies are described under the heading "Management's Discussion and Analysis of Financial Condition and Results of Operations—Critical Accounting Policies and Significant Judgments and Estimates" in the Form 10-K. There have been no material changes in our critical accounting policies and estimates in the preparation of our condensed consolidated financial statements during the nine months ended September 30, 2025 compared to those disclosed in the Form 10-K.

***Emerging Growth Company and Smaller Reporting Company Status***

We are a smaller reporting company and an emerging growth company, as defined under the Jumpstart Our Business Startup ("JOBS") Act. Under the JOBS Act, emerging growth companies can delay the adoption of new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. Other exemptions and reduced reporting requirements under the JOBS Act for emerging growth companies include presentation of only two years of audited financial statements in a registration statement for an initial public offering, an exemption from the requirement to provide an auditor's report on internal controls over financial reporting pursuant to Sarbanes-Oxley Act of 2002, as amended ("Sarbanes-Oxley"), an exemption from any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation, and less extensive disclosure about our executive compensation arrangements.

We have elected to use the extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that (i) we are no longer an emerging growth company or (ii) we affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, our condensed consolidated financial statements may not be comparable to companies that comply with new or revised accounting standards as of public company effective dates.

We will remain an emerging growth company until the earliest of (i) December 31, 2026, (ii) the last day of our first fiscal year in which we have total annual gross revenue of $1.235 billion or more, (iii) the date on which we are deemed to be a "large accelerated filer," as defined in Rule 12b-2 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), which means the market value of equity securities that is held by non-affiliates exceeds $700 million as of the last business day of our most recently completed second fiscal quarter and (iv) the date on which we have issued more than $1.0 billion in non-convertible debt securities during the prior three-year period.

------

<u>[**Table of Contents**](#i48b4e94dc81c43c39c91c977a31d007f_13)</u> 

Even after we no longer qualify as an emerging growth company, we may still qualify as a "smaller reporting company" and/or "non-accelerated filer" which may allow us to take advantage of many of the same exemptions from disclosure requirements including not being required to comply for a period of time with the auditor attestation requirements of Section 404 of Sarbanes-Oxley, and reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements.

**Item 3. Quantitative and Qualitative Disclosures About Market Risk**

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item.

**Item 4. Controls and Procedures**

**Definition and Limitations of Disclosure Controls**

Our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed under the Exchange Act, such as this Quarterly Report on Form 10-Q, is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms. Disclosure controls and procedures are also designed to ensure that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure. Our management evaluates these controls and procedures on an ongoing basis. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

**Evaluation of Disclosure Controls and Procedures**

Our management, with the participation of our President and Chief Executive Officer, our principal executive officer, and our Chief Strategy and Financial Officer, our principal accounting and financial officer, have evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of September 30, 2025.

Based on the evaluation of our disclosure controls and procedures, our President and Chief Executive Officer and our Chief Strategy and Financial Officer concluded that our disclosure controls and procedures were effective as of September 30, 2025.

**Changes in Internal Control Over Financial Reporting**

There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f)) under the Exchange Act) that occurred during the quarter ended September 30, 2025, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

------

<u>[**Table of Contents**](#i48b4e94dc81c43c39c91c977a31d007f_13)</u> 

**Part II OTHER INFORMATION**

**Item 1. Legal Proceedings**

From time to time, we may be subject to various legal proceedings, claims and administrative proceedings that arise in the ordinary course of our business activities or otherwise. Although the results of the litigation and claims cannot be predicted with certainty, as of the date of this report, we do not believe we are party to any claim, proceeding or litigation the outcome of which, if determined adversely to us, would individually or in the aggregate be reasonably expected to have a material adverse effect on our business. The outcome of any future litigation is uncertain. Such litigation, if not resolved, could result in substantial costs to us, including any costs associated with the indemnification of directors and officers.

------

<u>[**Table of Contents**](#i48b4e94dc81c43c39c91c977a31d007f_13)</u> 

**Item 1A. Risk Factors**

Investing in our common stock involves a high degree of risk. You should carefully consider the risk factors, described in the sections titled "Risk Factors" in the Form 10-K and our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2025 and June 30, 2025, as well as the other information in this Quarterly Report on Form 10-Q, before deciding whether to invest in shares of our common stock. There have been no material changes in our risk factors from those described in the Form 10-K, other than as described in our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2025 and June 30, 2025.

------

<u>[**Table of Contents**](#i48b4e94dc81c43c39c91c977a31d007f_13)</u> 

**Item 2. Unregistered Sales of Equity Securities and Use of Proceeds**

None.

**Item 3. Defaults Upon Senior Securities**

None.

**Item 4. Mine Safety Disclosures**

None.

**Item 5. Other Information**

During the fiscal quarter ended September 30, 2025, none of our directors or executive officers adopted, modified or terminated any contract, instruction or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any "non-Rule 10b5-1 trading arrangement."

------

<u>[**Table of Contents**](#i48b4e94dc81c43c39c91c977a31d007f_13)</u> 

**Item 6. Exhibits** 

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Exhibit <br>Number** | **Exhibit <br>Description** | **Incorporated by Reference** | **Incorporated by Reference** | **Incorporated by Reference** | **Filed Herewith** |
| **Exhibit <br>Number** | **Exhibit <br>Description** | **Form** | **Date** | **Number** | **Filed Herewith** |
| 31.1 | <u>[Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](elicio10-qxexhibit311.htm)</u> |  |  |  | X |
| 31.2 | <u>[Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](elicio10-qxexhibit312.htm)</u> |  |  |  | X |
| 32.1^ | <u>[Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](elicio10-qxexhibit321.htm)</u> |  |  |  | X |
| 32.2^ | <u>[Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](elicio10-qxexhibit322.htm)</u> |  |  |  | X |
| 101.INS | XBRL Instance Document. |  |  |  | X |
| 101.SCH | XBRL Taxonomy Extension Schema Document. |  |  |  | X |
| 101.CAL | XBRL Taxonomy Extension Calculation Linkbase Document. |  |  |  | X |
| 101.DEF | XBRL Taxonomy Extension Definition Linkbase Document. |  |  |  | X |
| 101.LAB | XBRL Taxonomy Extension Label Linkbase Document. |  |  |  | X |
| 101.PRE | XBRL Taxonomy Extension Presentation Linkbase Document. |  |  |  | X |
| 104 | Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101). |  |  |  | X |

---

__________________________________

^ The certification that accompanies this Quarterly Report on Form 10-Q pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, is not deemed "filed" by the Registrant for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.

------

<u>[**Table of Contents**](#i48b4e94dc81c43c39c91c977a31d007f_13)</u> 

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
| | | **ELICIO THERAPEUTICS, INC.** | **ELICIO THERAPEUTICS, INC.** |
| | | By: | /s/ ROBERT CONNELLY |
| Date: | November 13, 2025 |  | Robert Connelly <br>*President and Chief Executive Officer* <br>*(Principal Executive Officer)* |

---

---

| | | | |
|:---|:---|:---|:---|
| | | By: | /s/ PREETAM SHAH |
| Date: | November 13, 2025 |  | Preetam Shah <br>*Chief Strategy and Financial Officer*<br>*(Principal Financial Officer and Principal Accounting Officer)* |

---

## Exhibit 31.1

![](elicio10-qxexhibit311001.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exhibit 31.1 CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Robert Connelly, certify that: 1. I have reviewed this Quarterly Report on Form 10-Q of Elicio Therapeutics, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to me by others within those entities, particularly during the period in which this report is being prepared; b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and 5. I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

------

![](elicio10-qxexhibit311002.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. ELICIO THERAPEUTICS, INC. By: /s/ Robert Connelly Robert Connelly President and Chief Executive Officer (Principal Executive Officer) Date: November 13, 2025

------

## Exhibit 31.2

![](elicio10-qxexhibit312001.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exhibit 31.2 CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Preetam Shah, certify that: 1. I have reviewed this Quarterly Report on Form 10-Q of Elicio Therapeutics, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to me by others within those entities, particularly during the period in which this report is being prepared; b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and 5. I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

------

![](elicio10-qxexhibit312002.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. ELICIO THERAPEUTICS, INC. By: /s/ Preetam Shah Preetam Shah Chief Strategy and Financial Officer (Principal Financial Officer and Principal Accounting Officer) Date: November 13, 2025

------

## Exhibit 32.1

![](elicio10-qxexhibit321001.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exhibit 32.1 CERTIFICATIONS PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (18 U.S.C. SECTION 1350) The undersigned officer of Elicio Therapeutics, Inc. (the "Company") certifies to such officer's knowledge, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes- Oxley Act of 2002, that: 1. The Quarterly Report on Form 10-Q of the Company for the period ended September 30, 2025 (the "Quarterly Report"), as filed with the Securities and Exchange Commission, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and 2. The information contained in this Quarterly Report fairly presents, in all material respects, the financial condition and results of operations of the Company. ELICIO THERAPEUTICS, INC. By: /s/ Robert Connelly Robert Connelly President and Chief Executive Officer (Principal Executive Officer) Date: November 13, 2025

------

## Exhibit 32.2

![](elicio10-qxexhibit322001.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exhibit 32.2 CERTIFICATIONS PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (18 U.S.C. SECTION 1350) The undersigned officer of Elicio Therapeutics, Inc. (the "Company") certifies to such officer's knowledge, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes- Oxley Act of 2002, that: 1. The Quarterly Report on Form 10-Q of the Company for the period ended September 30, 2025 (the "Quarterly Report"), as filed with the Securities and Exchange Commission, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and 2. The information contained in this Quarterly Report fairly presents, in all material respects, the financial condition and results of operations of the Company. ELICIO THERAPEUTICS, INC. By: /s/ Preetam Shah Preetam Shah Chief Strategy and Financial Officer (Principal Financial Officer and Principal Accounting Officer) Date: November 13, 2025

------